Global Injectable Drug Delivery research

Injectable Drug Delivery Comprehensive Study by Type (Devices, Conventional Injection Device {Prefilled Syringes and Fillable Syringes}, Self-injection Devices {Needle-Free Injectors (NFI), Wearable Injectors, Pen Injectors and Auto-Injectors}, Auto Injectors, Pen Injectors, Wearable Injectors, Other Devices), Application (Aesthetics, Autoimmune Diseases, Hormonal Disorders, Infectious Diseases, Oncology, Pain Management), Formulations (Conventional Drug Delivery Formulations, Novel Drug Delivery Formulations), Formulation Packaging (Ampules, Vials, Cartridges, Bottles), Facility of Use (Hospitals and Clinics, Home Care Settings, Other Facilities of Use), Distribution Channel (Hospitals, Retail Pharmacy Stores), Usage Pattern (Curative Care, Immunization, Other Usage), Therapeutic Application (Auto-immune diseases, Hormonal Disorders, Orphan Diseases, Oncology, Other Therapeutic Applications), Site of Administration (Skin {Intradermal and Subcutaneous}, Circulatory/Musculoskeletal{ Intravenous, Intracardiac, Intramuscular, and Intraperitoneal}, Organs {Intravitreal and Intra-Articular}, Central Nervous System {Intracerebral and Intrathecal}), Devices (Conventional Injection Device {Prefilled Syringes and Fillable Syringes}, Self-injection Devices {Needle-Free Injectors (NFI), Wearable Injectors, Pen Injectors and Auto-Injectors}, Auto Injectors, Pen Injectors, Wearable Injectors, Other Devices), End User (Hospitals/Clinics, Home Care Settings, Research Laboratories, Pharmaceutical and Biotechnology Companies, Other End Users) Players and Region - Global Market Outlook to 2030

Injectable Drug Delivery Market by XX Submarkets | Forecast Years 2024-2030 | CAGR: 8.4%  

Access Sample Report Make An Enquiry Before Purchase
  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
Industry Background:
Injectable Drug Delivery refers to a device used to penetrate needle or similar device into skin and facilitate the rapid transport of drug into the body by bypassing first pass metabolism. It helps patient in administrating drug in unconsciousness. Injectable drug delivery are widely used in conditions such as autoimmune diseases, cystic fibrosis, hormonal imbalance, pain, Wilson’s disease, hemophilia, hepatitis C and ribose-5-phosphate isomerase deficiency. The global injectable drug delivery market is growing significantly due to rising geriatric population, technological advancements in injectable drug delivery devices and increase in the number of cancer and diabetic patients globally. According to the report, the global population aged 60 years or over numbered 962 million in 2017, more than twice as large as in 1980 when there were 382 million older persons worldwide. The number of older persons is expected to double again by 2050, when it is projected to reach nearly 2.1 billion.

AttributesDetails
Study Period2017-2027
Base Year2021
High Growth MarketAsia-Pacific
UnitValue (USD Million)
Key Companies ProfiledDickinson and Company (United States), Baxter International (United States), Pfizer (United States), Gerresheimer AG (Germany), Schott AG (Germany), Eli Lilly and Company (United States), Terumo Corporation (Japan), Sandoz (Germany), Teva Pharmaceutical Industries Ltd. (Israel), Nova Nordisk A/S (Denmark) and Sanofi (France)


This growth is primarily driven by Rising Prevalence of Chronic Diseases Around The Globe, Increase In Targeted Drug R&D Activities and Growing Demand for Self-Injection Devices.

Globally, a noticeable market trend is evident High Penetrations of Self-Injection Techniques The Pharmaceuticals sector in the North America region has been increasing at a sustainable rate, and further growth is expected to be witnessed over the forecast period, owing to the robust investments and expansion in production facilities in the region. Major Players, such as Dickinson and Company (United States), Baxter International (United States), Pfizer (United States), Gerresheimer AG (Germany), Schott AG (Germany), Eli Lilly and Company (United States), Terumo Corporation (Japan), Sandoz (Germany), Teva Pharmaceutical Industries Ltd. (Israel), Nova Nordisk A/S (Denmark) and Sanofi (France), etc have either set up their manufacturing facilities or are planning to start new provision in the dominated region in the upcoming years. In recent days Industry Players have increased their R&D spending and oreover concentrating on formulation. The Study is also segmented by Conventional Drug Delivery Formulations that includes Suspensions, Solutions, Lyophilized Formulations and Emulsions and by Novel Drug Delivery Formulations which covers Micro particles and Colloidal Dispersions and Long-acting Formulations.

Key Developments in the Market:
In January 2019, Aurobindo Pharma Limited, a pharmaceutical manufacturing company has entered into a definitive agreement of seven cancer drugs of Spectrum Pharma for USD 300 million. The acquisition will launch pad for Acrotech and established presence in the branded market, which will line up the strategy to grow and diversify the business.
According to the Occupational Safety & Health Administration (OSHA) estimates, 5.6 million workers in the healthcare industry are at a risk of needle injuries.

Regulatory Insights:
"To ensure rational and safe use of injections globally, better injection safety practices are needed. The responsibility for ensuring injection safety rests with national governments, prescribers, administrators, receivers of injections and the wider community. The World Health Organization (WHO) acknowledges this responsibility of its member states and the challenges they face. Through the WHO Injection Safety programme and the Safe Injection Global Network (SIGN – whose secretariat is hosted by WHO), the organization demonstrates its commitment to preventing injection-related disease transmission for patients, health workers and the community at large, through the rational and safe use of injections. WHO and SIGN recognize the importance of infection prevention and control in injection safety."

Influencing Trend:
High Penetrations of Self-Injection Techniques and Innovations in Injectable Drug Delivery Systems

Market Growth Drivers:
Rising Prevalence of Chronic Diseases Around The Globe, Increase In Targeted Drug R&D Activities and Growing Demand for Self-Injection Devices

Challenges:
Preference for Other Modes of Drug Delivery

Restraints:
Substitutes For Injectable Drug Such As Oral and Transdermal Delivery, Risk of Transmission of Blood-Borne Infection with Needle Stick Injuries and High Manufacturing Cost

Opportunities:
Government Initiatives and Increasing Disposable Income, Reduction in the Frequency of Dosage Administration without Compromising the Effectiveness of the Treatment and Development of Bio similar in the Pharmaceutical Market

AMA Research follows a focused and realistic research framework that provides the ability to study the crucial market dynamics in several regions across the world. Moreover, an in-depth assessment is mostly conducted by our analysts on geographical regions to provide clients and businesses the opportunity to dominate in niche markets and expand in emerging markets across the globe. This market research study also showcases the spontaneously changing Players landscape impacting the growth of the market. Furthermore, our market researchers extensively analyze the products and services offered by multiple players competing to increase their market share and presence.

Customization in the Report
AMA Research features not only specific market forecasts but also includes significant value-added commentary on:
- Market Trends
- Technological Trends and Innovations
- Market Maturity Indicators
- Growth Drivers and Constraints in Injectable Drug Delivery Market
- Analysis about New Entrants in Injectable Drug Delivery Market & Entry/Exit Barriers
- To Seize Powerful Market Opportunities
- Identify Key Business Segments, Market Proposition & Gap Analysis
- An Unbiased Perspective towards Market Performance & Indicators

Against this Challenging Backdrop, Injectable Drug Delivery Study Sheds Light on
— The Injectable Drug Delivery Market status quo and key characteristics. To end this, Analysts at AMA organize and took surveys of the Injectable Drug Delivery industry Players. The resultant snapshot serves as a basis for understanding why and how the industry can be expected to change.
— Where Injectable Drug Delivery industry is heading and what are the top priorities. Insights are drawn from financial analysis, surveys, and interviews with key executives and industry experts.
— How every company in this diverse set of Players can best navigate the emerging competition landscape and follow a strategy that helps them position to hold the value they currently claim or capture the new addressable opportunity.

Report Objectives / Segmentation Covered

By Type
  • Devices
  • Conventional Injection Device {Prefilled Syringes and Fillable Syringes}
  • Self-injection Devices {Needle-Free Injectors (NFI), Wearable Injectors, Pen Injectors and Auto-Injectors}
  • Auto Injectors
  • Pen Injectors
  • Wearable Injectors
  • Other Devices
By Application
  • Aesthetics
  • Autoimmune Diseases
  • Hormonal Disorders
  • Infectious Diseases
  • Oncology
  • Pain Management
By Formulations
  • Conventional Drug Delivery Formulations
  • Novel Drug Delivery Formulations

By Formulation Packaging
  • Ampules
  • Vials
  • Cartridges
  • Bottles

By Facility of Use
  • Hospitals and Clinics
  • Home Care Settings
  • Other Facilities of Use

By Distribution Channel
  • Hospitals
  • Retail Pharmacy Stores

By Usage Pattern
  • Curative Care
  • Immunization
  • Other Usage

By Therapeutic Application
  • Auto-immune diseases
  • Hormonal Disorders
  • Orphan Diseases
  • Oncology
  • Other Therapeutic Applications

By Site of Administration
  • Skin {Intradermal and Subcutaneous}
  • Circulatory/Musculoskeletal{ Intravenous, Intracardiac, Intramuscular, and Intraperitoneal}
  • Organs {Intravitreal and Intra-Articular}
  • Central Nervous System {Intracerebral and Intrathecal}

By Devices
  • Conventional Injection Device {Prefilled Syringes and Fillable Syringes}
  • Self-injection Devices {Needle-Free Injectors (NFI), Wearable Injectors
  • Pen Injectors and Auto-Injectors}
  • Auto Injectors
  • Pen Injectors
  • Wearable Injectors
  • Other Devices

By End User
  • Hospitals/Clinics
  • Home Care Settings
  • Research Laboratories
  • Pharmaceutical and Biotechnology Companies
  • Other End Users

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Rising Prevalence of Chronic Diseases Around The Globe
      • 3.2.2. Increase In Targeted Drug R&D Activities
      • 3.2.3. Growing Demand for Self-Injection Devices
    • 3.3. Market Challenges
      • 3.3.1. Preference for Other Modes of Drug Delivery
    • 3.4. Market Trends
      • 3.4.1. High Penetrations of Self-Injection Techniques
      • 3.4.2. Innovations in Injectable Drug Delivery Systems
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Injectable Drug Delivery, by Type, Application, Formulations , Formulation Packaging, Facility of Use, Distribution Channel, Usage Pattern, Therapeutic Application, Site of Administration, Devices, End User and Region (value, volume and price ) (2016-2021)
    • 5.1. Introduction
    • 5.2. Global Injectable Drug Delivery (Value)
      • 5.2.1. Global Injectable Drug Delivery by: Type (Value)
        • 5.2.1.1. Devices
        • 5.2.1.2. Conventional Injection Device {Prefilled Syringes and Fillable Syringes}
        • 5.2.1.3. Self-injection Devices {Needle-Free Injectors (NFI), Wearable Injectors, Pen Injectors and Auto-Injectors}
        • 5.2.1.4. Auto Injectors
        • 5.2.1.5. Pen Injectors
        • 5.2.1.6. Wearable Injectors
        • 5.2.1.7. Other Devices
      • 5.2.2. Global Injectable Drug Delivery by: Application (Value)
        • 5.2.2.1. Aesthetics
        • 5.2.2.2. Autoimmune Diseases
        • 5.2.2.3. Hormonal Disorders
        • 5.2.2.4. Infectious Diseases
        • 5.2.2.5. Oncology
        • 5.2.2.6. Pain Management
      • 5.2.3. Global Injectable Drug Delivery by: Formulation Packaging (Value)
        • 5.2.3.1. Ampules
        • 5.2.3.2. Vials
        • 5.2.3.3. Cartridges
        • 5.2.3.4. Bottles
      • 5.2.4. Global Injectable Drug Delivery by: Facility of Use (Value)
        • 5.2.4.1. Hospitals and Clinics
        • 5.2.4.2. Home Care Settings
        • 5.2.4.3. Other Facilities of Use
      • 5.2.5. Global Injectable Drug Delivery by: Distribution Channel (Value)
        • 5.2.5.1. Hospitals
        • 5.2.5.2. Retail Pharmacy Stores
      • 5.2.6. Global Injectable Drug Delivery by: Usage Pattern (Value)
        • 5.2.6.1. Curative Care
        • 5.2.6.2. Immunization
        • 5.2.6.3. Other Usage
      • 5.2.7. Global Injectable Drug Delivery by: Therapeutic Application (Value)
        • 5.2.7.1. Auto-immune diseases
        • 5.2.7.2. Hormonal Disorders
        • 5.2.7.3. Orphan Diseases
        • 5.2.7.4. Oncology
        • 5.2.7.5. Other Therapeutic Applications
      • 5.2.8. Global Injectable Drug Delivery by: Site of Administration (Value)
        • 5.2.8.1. Skin {Intradermal and Subcutaneous}
        • 5.2.8.2. Circulatory/Musculoskeletal{ Intravenous, Intracardiac, Intramuscular, and Intraperitoneal}
        • 5.2.8.3. Organs {Intravitreal and Intra-Articular}
        • 5.2.8.4. Central Nervous System {Intracerebral and Intrathecal}
      • 5.2.9. Global Injectable Drug Delivery by: Devices (Value)
        • 5.2.9.1. Conventional Injection Device {Prefilled Syringes and Fillable Syringes}
        • 5.2.9.2. Self-injection Devices {Needle-Free Injectors (NFI), Wearable Injectors
        • 5.2.9.3. Pen Injectors and Auto-Injectors}
        • 5.2.9.4. Auto Injectors
        • 5.2.9.5. Pen Injectors
        • 5.2.9.6. Wearable Injectors
        • 5.2.9.7. Other Devices
      • 5.2.10. Global Injectable Drug Delivery by: End User (Value)
        • 5.2.10.1. Hospitals/Clinics
        • 5.2.10.2. Home Care Settings
        • 5.2.10.3. Research Laboratories
        • 5.2.10.4. Pharmaceutical and Biotechnology Companies
        • 5.2.10.5. Other End Users
      • 5.2.11. Global Injectable Drug Delivery Region
        • 5.2.11.1. South America
          • 5.2.11.1.1. Brazil
          • 5.2.11.1.2. Argentina
          • 5.2.11.1.3. Rest of South America
        • 5.2.11.2. Asia Pacific
          • 5.2.11.2.1. China
          • 5.2.11.2.2. Japan
          • 5.2.11.2.3. India
          • 5.2.11.2.4. South Korea
          • 5.2.11.2.5. Taiwan
          • 5.2.11.2.6. Australia
          • 5.2.11.2.7. Rest of Asia-Pacific
        • 5.2.11.3. Europe
          • 5.2.11.3.1. Germany
          • 5.2.11.3.2. France
          • 5.2.11.3.3. Italy
          • 5.2.11.3.4. United Kingdom
          • 5.2.11.3.5. Netherlands
          • 5.2.11.3.6. Rest of Europe
        • 5.2.11.4. MEA
          • 5.2.11.4.1. Middle East
          • 5.2.11.4.2. Africa
        • 5.2.11.5. North America
          • 5.2.11.5.1. United States
          • 5.2.11.5.2. Canada
          • 5.2.11.5.3. Mexico
    • 5.3. Global Injectable Drug Delivery (Volume)
      • 5.3.1. Global Injectable Drug Delivery by: Type (Volume)
        • 5.3.1.1. Devices
        • 5.3.1.2. Conventional Injection Device {Prefilled Syringes and Fillable Syringes}
        • 5.3.1.3. Self-injection Devices {Needle-Free Injectors (NFI), Wearable Injectors, Pen Injectors and Auto-Injectors}
        • 5.3.1.4. Auto Injectors
        • 5.3.1.5. Pen Injectors
        • 5.3.1.6. Wearable Injectors
        • 5.3.1.7. Other Devices
      • 5.3.2. Global Injectable Drug Delivery by: Application (Volume)
        • 5.3.2.1. Aesthetics
        • 5.3.2.2. Autoimmune Diseases
        • 5.3.2.3. Hormonal Disorders
        • 5.3.2.4. Infectious Diseases
        • 5.3.2.5. Oncology
        • 5.3.2.6. Pain Management
      • 5.3.3. Global Injectable Drug Delivery by: Formulation Packaging (Volume)
        • 5.3.3.1. Ampules
        • 5.3.3.2. Vials
        • 5.3.3.3. Cartridges
        • 5.3.3.4. Bottles
      • 5.3.4. Global Injectable Drug Delivery by: Facility of Use (Volume)
        • 5.3.4.1. Hospitals and Clinics
        • 5.3.4.2. Home Care Settings
        • 5.3.4.3. Other Facilities of Use
      • 5.3.5. Global Injectable Drug Delivery by: Distribution Channel (Volume)
        • 5.3.5.1. Hospitals
        • 5.3.5.2. Retail Pharmacy Stores
      • 5.3.6. Global Injectable Drug Delivery by: Usage Pattern (Volume)
        • 5.3.6.1. Curative Care
        • 5.3.6.2. Immunization
        • 5.3.6.3. Other Usage
      • 5.3.7. Global Injectable Drug Delivery by: Therapeutic Application (Volume)
        • 5.3.7.1. Auto-immune diseases
        • 5.3.7.2. Hormonal Disorders
        • 5.3.7.3. Orphan Diseases
        • 5.3.7.4. Oncology
        • 5.3.7.5. Other Therapeutic Applications
      • 5.3.8. Global Injectable Drug Delivery by: Site of Administration (Volume)
        • 5.3.8.1. Skin {Intradermal and Subcutaneous}
        • 5.3.8.2. Circulatory/Musculoskeletal{ Intravenous, Intracardiac, Intramuscular, and Intraperitoneal}
        • 5.3.8.3. Organs {Intravitreal and Intra-Articular}
        • 5.3.8.4. Central Nervous System {Intracerebral and Intrathecal}
      • 5.3.9. Global Injectable Drug Delivery by: Devices (Volume)
        • 5.3.9.1. Conventional Injection Device {Prefilled Syringes and Fillable Syringes}
        • 5.3.9.2. Self-injection Devices {Needle-Free Injectors (NFI), Wearable Injectors
        • 5.3.9.3. Pen Injectors and Auto-Injectors}
        • 5.3.9.4. Auto Injectors
        • 5.3.9.5. Pen Injectors
        • 5.3.9.6. Wearable Injectors
        • 5.3.9.7. Other Devices
      • 5.3.10. Global Injectable Drug Delivery by: End User (Volume)
        • 5.3.10.1. Hospitals/Clinics
        • 5.3.10.2. Home Care Settings
        • 5.3.10.3. Research Laboratories
        • 5.3.10.4. Pharmaceutical and Biotechnology Companies
        • 5.3.10.5. Other End Users
      • 5.3.11. Global Injectable Drug Delivery Region
        • 5.3.11.1. South America
          • 5.3.11.1.1. Brazil
          • 5.3.11.1.2. Argentina
          • 5.3.11.1.3. Rest of South America
        • 5.3.11.2. Asia Pacific
          • 5.3.11.2.1. China
          • 5.3.11.2.2. Japan
          • 5.3.11.2.3. India
          • 5.3.11.2.4. South Korea
          • 5.3.11.2.5. Taiwan
          • 5.3.11.2.6. Australia
          • 5.3.11.2.7. Rest of Asia-Pacific
        • 5.3.11.3. Europe
          • 5.3.11.3.1. Germany
          • 5.3.11.3.2. France
          • 5.3.11.3.3. Italy
          • 5.3.11.3.4. United Kingdom
          • 5.3.11.3.5. Netherlands
          • 5.3.11.3.6. Rest of Europe
        • 5.3.11.4. MEA
          • 5.3.11.4.1. Middle East
          • 5.3.11.4.2. Africa
        • 5.3.11.5. North America
          • 5.3.11.5.1. United States
          • 5.3.11.5.2. Canada
          • 5.3.11.5.3. Mexico
    • 5.4. Global Injectable Drug Delivery (Price)
      • 5.4.1. Global Injectable Drug Delivery by: Type (Price)
  • 6. Injectable Drug Delivery: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2021)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Dickinson and Company (United States)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Baxter International (United States)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Pfizer (United States)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Gerresheimer AG (Germany)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Schott AG (Germany)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Eli Lilly and Company (United States)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Terumo Corporation (Japan)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Sandoz (Germany)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. Teva Pharmaceutical Industries Ltd. (Israel)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. Nova Nordisk A/S (Denmark)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
      • 6.4.11. Sanofi (France)
        • 6.4.11.1. Business Overview
        • 6.4.11.2. Products/Services Offerings
        • 6.4.11.3. Financial Analysis
        • 6.4.11.4. SWOT Analysis
  • 7. Global Injectable Drug Delivery Sale, by Type, Application, Formulations , Formulation Packaging, Facility of Use, Distribution Channel, Usage Pattern, Therapeutic Application, Site of Administration, Devices, End User and Region (value, volume and price ) (2022-2027)
    • 7.1. Introduction
    • 7.2. Global Injectable Drug Delivery (Value)
      • 7.2.1. Global Injectable Drug Delivery by: Type (Value)
        • 7.2.1.1. Devices
        • 7.2.1.2. Conventional Injection Device {Prefilled Syringes and Fillable Syringes}
        • 7.2.1.3. Self-injection Devices {Needle-Free Injectors (NFI), Wearable Injectors, Pen Injectors and Auto-Injectors}
        • 7.2.1.4. Auto Injectors
        • 7.2.1.5. Pen Injectors
        • 7.2.1.6. Wearable Injectors
        • 7.2.1.7. Other Devices
      • 7.2.2. Global Injectable Drug Delivery by: Application (Value)
        • 7.2.2.1. Aesthetics
        • 7.2.2.2. Autoimmune Diseases
        • 7.2.2.3. Hormonal Disorders
        • 7.2.2.4. Infectious Diseases
        • 7.2.2.5. Oncology
        • 7.2.2.6. Pain Management
      • 7.2.3. Global Injectable Drug Delivery by: Formulation Packaging (Value)
        • 7.2.3.1. Ampules
        • 7.2.3.2. Vials
        • 7.2.3.3. Cartridges
        • 7.2.3.4. Bottles
      • 7.2.4. Global Injectable Drug Delivery by: Facility of Use (Value)
        • 7.2.4.1. Hospitals and Clinics
        • 7.2.4.2. Home Care Settings
        • 7.2.4.3. Other Facilities of Use
      • 7.2.5. Global Injectable Drug Delivery by: Distribution Channel (Value)
        • 7.2.5.1. Hospitals
        • 7.2.5.2. Retail Pharmacy Stores
      • 7.2.6. Global Injectable Drug Delivery by: Usage Pattern (Value)
        • 7.2.6.1. Curative Care
        • 7.2.6.2. Immunization
        • 7.2.6.3. Other Usage
      • 7.2.7. Global Injectable Drug Delivery by: Therapeutic Application (Value)
        • 7.2.7.1. Auto-immune diseases
        • 7.2.7.2. Hormonal Disorders
        • 7.2.7.3. Orphan Diseases
        • 7.2.7.4. Oncology
        • 7.2.7.5. Other Therapeutic Applications
      • 7.2.8. Global Injectable Drug Delivery by: Site of Administration (Value)
        • 7.2.8.1. Skin {Intradermal and Subcutaneous}
        • 7.2.8.2. Circulatory/Musculoskeletal{ Intravenous, Intracardiac, Intramuscular, and Intraperitoneal}
        • 7.2.8.3. Organs {Intravitreal and Intra-Articular}
        • 7.2.8.4. Central Nervous System {Intracerebral and Intrathecal}
      • 7.2.9. Global Injectable Drug Delivery by: Devices (Value)
        • 7.2.9.1. Conventional Injection Device {Prefilled Syringes and Fillable Syringes}
        • 7.2.9.2. Self-injection Devices {Needle-Free Injectors (NFI), Wearable Injectors
        • 7.2.9.3. Pen Injectors and Auto-Injectors}
        • 7.2.9.4. Auto Injectors
        • 7.2.9.5. Pen Injectors
        • 7.2.9.6. Wearable Injectors
        • 7.2.9.7. Other Devices
      • 7.2.10. Global Injectable Drug Delivery by: End User (Value)
        • 7.2.10.1. Hospitals/Clinics
        • 7.2.10.2. Home Care Settings
        • 7.2.10.3. Research Laboratories
        • 7.2.10.4. Pharmaceutical and Biotechnology Companies
        • 7.2.10.5. Other End Users
      • 7.2.11. Global Injectable Drug Delivery Region
        • 7.2.11.1. South America
          • 7.2.11.1.1. Brazil
          • 7.2.11.1.2. Argentina
          • 7.2.11.1.3. Rest of South America
        • 7.2.11.2. Asia Pacific
          • 7.2.11.2.1. China
          • 7.2.11.2.2. Japan
          • 7.2.11.2.3. India
          • 7.2.11.2.4. South Korea
          • 7.2.11.2.5. Taiwan
          • 7.2.11.2.6. Australia
          • 7.2.11.2.7. Rest of Asia-Pacific
        • 7.2.11.3. Europe
          • 7.2.11.3.1. Germany
          • 7.2.11.3.2. France
          • 7.2.11.3.3. Italy
          • 7.2.11.3.4. United Kingdom
          • 7.2.11.3.5. Netherlands
          • 7.2.11.3.6. Rest of Europe
        • 7.2.11.4. MEA
          • 7.2.11.4.1. Middle East
          • 7.2.11.4.2. Africa
        • 7.2.11.5. North America
          • 7.2.11.5.1. United States
          • 7.2.11.5.2. Canada
          • 7.2.11.5.3. Mexico
    • 7.3. Global Injectable Drug Delivery (Volume)
      • 7.3.1. Global Injectable Drug Delivery by: Type (Volume)
        • 7.3.1.1. Devices
        • 7.3.1.2. Conventional Injection Device {Prefilled Syringes and Fillable Syringes}
        • 7.3.1.3. Self-injection Devices {Needle-Free Injectors (NFI), Wearable Injectors, Pen Injectors and Auto-Injectors}
        • 7.3.1.4. Auto Injectors
        • 7.3.1.5. Pen Injectors
        • 7.3.1.6. Wearable Injectors
        • 7.3.1.7. Other Devices
      • 7.3.2. Global Injectable Drug Delivery by: Application (Volume)
        • 7.3.2.1. Aesthetics
        • 7.3.2.2. Autoimmune Diseases
        • 7.3.2.3. Hormonal Disorders
        • 7.3.2.4. Infectious Diseases
        • 7.3.2.5. Oncology
        • 7.3.2.6. Pain Management
      • 7.3.3. Global Injectable Drug Delivery by: Formulation Packaging (Volume)
        • 7.3.3.1. Ampules
        • 7.3.3.2. Vials
        • 7.3.3.3. Cartridges
        • 7.3.3.4. Bottles
      • 7.3.4. Global Injectable Drug Delivery by: Facility of Use (Volume)
        • 7.3.4.1. Hospitals and Clinics
        • 7.3.4.2. Home Care Settings
        • 7.3.4.3. Other Facilities of Use
      • 7.3.5. Global Injectable Drug Delivery by: Distribution Channel (Volume)
        • 7.3.5.1. Hospitals
        • 7.3.5.2. Retail Pharmacy Stores
      • 7.3.6. Global Injectable Drug Delivery by: Usage Pattern (Volume)
        • 7.3.6.1. Curative Care
        • 7.3.6.2. Immunization
        • 7.3.6.3. Other Usage
      • 7.3.7. Global Injectable Drug Delivery by: Therapeutic Application (Volume)
        • 7.3.7.1. Auto-immune diseases
        • 7.3.7.2. Hormonal Disorders
        • 7.3.7.3. Orphan Diseases
        • 7.3.7.4. Oncology
        • 7.3.7.5. Other Therapeutic Applications
      • 7.3.8. Global Injectable Drug Delivery by: Site of Administration (Volume)
        • 7.3.8.1. Skin {Intradermal and Subcutaneous}
        • 7.3.8.2. Circulatory/Musculoskeletal{ Intravenous, Intracardiac, Intramuscular, and Intraperitoneal}
        • 7.3.8.3. Organs {Intravitreal and Intra-Articular}
        • 7.3.8.4. Central Nervous System {Intracerebral and Intrathecal}
      • 7.3.9. Global Injectable Drug Delivery by: Devices (Volume)
        • 7.3.9.1. Conventional Injection Device {Prefilled Syringes and Fillable Syringes}
        • 7.3.9.2. Self-injection Devices {Needle-Free Injectors (NFI), Wearable Injectors
        • 7.3.9.3. Pen Injectors and Auto-Injectors}
        • 7.3.9.4. Auto Injectors
        • 7.3.9.5. Pen Injectors
        • 7.3.9.6. Wearable Injectors
        • 7.3.9.7. Other Devices
      • 7.3.10. Global Injectable Drug Delivery by: End User (Volume)
        • 7.3.10.1. Hospitals/Clinics
        • 7.3.10.2. Home Care Settings
        • 7.3.10.3. Research Laboratories
        • 7.3.10.4. Pharmaceutical and Biotechnology Companies
        • 7.3.10.5. Other End Users
      • 7.3.11. Global Injectable Drug Delivery Region
        • 7.3.11.1. South America
          • 7.3.11.1.1. Brazil
          • 7.3.11.1.2. Argentina
          • 7.3.11.1.3. Rest of South America
        • 7.3.11.2. Asia Pacific
          • 7.3.11.2.1. China
          • 7.3.11.2.2. Japan
          • 7.3.11.2.3. India
          • 7.3.11.2.4. South Korea
          • 7.3.11.2.5. Taiwan
          • 7.3.11.2.6. Australia
          • 7.3.11.2.7. Rest of Asia-Pacific
        • 7.3.11.3. Europe
          • 7.3.11.3.1. Germany
          • 7.3.11.3.2. France
          • 7.3.11.3.3. Italy
          • 7.3.11.3.4. United Kingdom
          • 7.3.11.3.5. Netherlands
          • 7.3.11.3.6. Rest of Europe
        • 7.3.11.4. MEA
          • 7.3.11.4.1. Middle East
          • 7.3.11.4.2. Africa
        • 7.3.11.5. North America
          • 7.3.11.5.1. United States
          • 7.3.11.5.2. Canada
          • 7.3.11.5.3. Mexico
    • 7.4. Global Injectable Drug Delivery (Price)
      • 7.4.1. Global Injectable Drug Delivery by: Type (Price)
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Injectable Drug Delivery: by Type(USD Million)
  • Table 2. Injectable Drug Delivery Devices , by Region USD Million (2016-2021)
  • Table 3. Injectable Drug Delivery Conventional Injection Device {Prefilled Syringes and Fillable Syringes} , by Region USD Million (2016-2021)
  • Table 4. Injectable Drug Delivery Self-injection Devices {Needle-Free Injectors (NFI), Wearable Injectors, Pen Injectors and Auto-Injectors} , by Region USD Million (2016-2021)
  • Table 5. Injectable Drug Delivery Auto Injectors , by Region USD Million (2016-2021)
  • Table 6. Injectable Drug Delivery Pen Injectors , by Region USD Million (2016-2021)
  • Table 7. Injectable Drug Delivery Wearable Injectors , by Region USD Million (2016-2021)
  • Table 8. Injectable Drug Delivery Other Devices , by Region USD Million (2016-2021)
  • Table 9. Injectable Drug Delivery: by Application(USD Million)
  • Table 10. Injectable Drug Delivery Aesthetics , by Region USD Million (2016-2021)
  • Table 11. Injectable Drug Delivery Autoimmune Diseases , by Region USD Million (2016-2021)
  • Table 12. Injectable Drug Delivery Hormonal Disorders , by Region USD Million (2016-2021)
  • Table 13. Injectable Drug Delivery Infectious Diseases , by Region USD Million (2016-2021)
  • Table 14. Injectable Drug Delivery Oncology , by Region USD Million (2016-2021)
  • Table 15. Injectable Drug Delivery Pain Management , by Region USD Million (2016-2021)
  • Table 16. Injectable Drug Delivery: by Formulation Packaging(USD Million)
  • Table 17. Injectable Drug Delivery Ampules , by Region USD Million (2016-2021)
  • Table 18. Injectable Drug Delivery Vials , by Region USD Million (2016-2021)
  • Table 19. Injectable Drug Delivery Cartridges , by Region USD Million (2016-2021)
  • Table 20. Injectable Drug Delivery Bottles , by Region USD Million (2016-2021)
  • Table 21. Injectable Drug Delivery: by Facility of Use(USD Million)
  • Table 22. Injectable Drug Delivery Hospitals and Clinics , by Region USD Million (2016-2021)
  • Table 23. Injectable Drug Delivery Home Care Settings , by Region USD Million (2016-2021)
  • Table 24. Injectable Drug Delivery Other Facilities of Use , by Region USD Million (2016-2021)
  • Table 25. Injectable Drug Delivery: by Distribution Channel(USD Million)
  • Table 26. Injectable Drug Delivery Hospitals , by Region USD Million (2016-2021)
  • Table 27. Injectable Drug Delivery Retail Pharmacy Stores , by Region USD Million (2016-2021)
  • Table 28. Injectable Drug Delivery: by Usage Pattern(USD Million)
  • Table 29. Injectable Drug Delivery Curative Care , by Region USD Million (2016-2021)
  • Table 30. Injectable Drug Delivery Immunization , by Region USD Million (2016-2021)
  • Table 31. Injectable Drug Delivery Other Usage , by Region USD Million (2016-2021)
  • Table 32. Injectable Drug Delivery: by Therapeutic Application(USD Million)
  • Table 33. Injectable Drug Delivery Auto-immune diseases , by Region USD Million (2016-2021)
  • Table 34. Injectable Drug Delivery Hormonal Disorders , by Region USD Million (2016-2021)
  • Table 35. Injectable Drug Delivery Orphan Diseases , by Region USD Million (2016-2021)
  • Table 36. Injectable Drug Delivery Oncology , by Region USD Million (2016-2021)
  • Table 37. Injectable Drug Delivery Other Therapeutic Applications , by Region USD Million (2016-2021)
  • Table 38. Injectable Drug Delivery: by Site of Administration(USD Million)
  • Table 39. Injectable Drug Delivery Skin {Intradermal and Subcutaneous} , by Region USD Million (2016-2021)
  • Table 40. Injectable Drug Delivery Circulatory/Musculoskeletal{ Intravenous, Intracardiac, Intramuscular, and Intraperitoneal} , by Region USD Million (2016-2021)
  • Table 41. Injectable Drug Delivery Organs {Intravitreal and Intra-Articular} , by Region USD Million (2016-2021)
  • Table 42. Injectable Drug Delivery Central Nervous System {Intracerebral and Intrathecal} , by Region USD Million (2016-2021)
  • Table 43. Injectable Drug Delivery: by Devices(USD Million)
  • Table 44. Injectable Drug Delivery Conventional Injection Device {Prefilled Syringes and Fillable Syringes} , by Region USD Million (2016-2021)
  • Table 45. Injectable Drug Delivery Self-injection Devices {Needle-Free Injectors (NFI), Wearable Injectors , by Region USD Million (2016-2021)
  • Table 46. Injectable Drug Delivery Pen Injectors and Auto-Injectors} , by Region USD Million (2016-2021)
  • Table 47. Injectable Drug Delivery Auto Injectors , by Region USD Million (2016-2021)
  • Table 48. Injectable Drug Delivery Pen Injectors , by Region USD Million (2016-2021)
  • Table 49. Injectable Drug Delivery Wearable Injectors , by Region USD Million (2016-2021)
  • Table 50. Injectable Drug Delivery Other Devices , by Region USD Million (2016-2021)
  • Table 51. Injectable Drug Delivery: by End User(USD Million)
  • Table 52. Injectable Drug Delivery Hospitals/Clinics , by Region USD Million (2016-2021)
  • Table 53. Injectable Drug Delivery Home Care Settings , by Region USD Million (2016-2021)
  • Table 54. Injectable Drug Delivery Research Laboratories , by Region USD Million (2016-2021)
  • Table 55. Injectable Drug Delivery Pharmaceutical and Biotechnology Companies , by Region USD Million (2016-2021)
  • Table 56. Injectable Drug Delivery Other End Users , by Region USD Million (2016-2021)
  • Table 57. South America Injectable Drug Delivery, by Country USD Million (2016-2021)
  • Table 58. South America Injectable Drug Delivery, by Type USD Million (2016-2021)
  • Table 59. South America Injectable Drug Delivery, by Application USD Million (2016-2021)
  • Table 60. South America Injectable Drug Delivery, by Formulations USD Million (2016-2021)
  • Table 61. South America Injectable Drug Delivery, by Formulation Packaging USD Million (2016-2021)
  • Table 62. South America Injectable Drug Delivery, by Facility of Use USD Million (2016-2021)
  • Table 63. South America Injectable Drug Delivery, by Distribution Channel USD Million (2016-2021)
  • Table 64. South America Injectable Drug Delivery, by Usage Pattern USD Million (2016-2021)
  • Table 65. South America Injectable Drug Delivery, by Therapeutic Application USD Million (2016-2021)
  • Table 66. South America Injectable Drug Delivery, by Site of Administration USD Million (2016-2021)
  • Table 67. South America Injectable Drug Delivery, by Devices USD Million (2016-2021)
  • Table 68. South America Injectable Drug Delivery, by End User USD Million (2016-2021)
  • Table 69. Brazil Injectable Drug Delivery, by Type USD Million (2016-2021)
  • Table 70. Brazil Injectable Drug Delivery, by Application USD Million (2016-2021)
  • Table 71. Brazil Injectable Drug Delivery, by Formulations USD Million (2016-2021)
  • Table 72. Brazil Injectable Drug Delivery, by Formulation Packaging USD Million (2016-2021)
  • Table 73. Brazil Injectable Drug Delivery, by Facility of Use USD Million (2016-2021)
  • Table 74. Brazil Injectable Drug Delivery, by Distribution Channel USD Million (2016-2021)
  • Table 75. Brazil Injectable Drug Delivery, by Usage Pattern USD Million (2016-2021)
  • Table 76. Brazil Injectable Drug Delivery, by Therapeutic Application USD Million (2016-2021)
  • Table 77. Brazil Injectable Drug Delivery, by Site of Administration USD Million (2016-2021)
  • Table 78. Brazil Injectable Drug Delivery, by Devices USD Million (2016-2021)
  • Table 79. Brazil Injectable Drug Delivery, by End User USD Million (2016-2021)
  • Table 80. Argentina Injectable Drug Delivery, by Type USD Million (2016-2021)
  • Table 81. Argentina Injectable Drug Delivery, by Application USD Million (2016-2021)
  • Table 82. Argentina Injectable Drug Delivery, by Formulations USD Million (2016-2021)
  • Table 83. Argentina Injectable Drug Delivery, by Formulation Packaging USD Million (2016-2021)
  • Table 84. Argentina Injectable Drug Delivery, by Facility of Use USD Million (2016-2021)
  • Table 85. Argentina Injectable Drug Delivery, by Distribution Channel USD Million (2016-2021)
  • Table 86. Argentina Injectable Drug Delivery, by Usage Pattern USD Million (2016-2021)
  • Table 87. Argentina Injectable Drug Delivery, by Therapeutic Application USD Million (2016-2021)
  • Table 88. Argentina Injectable Drug Delivery, by Site of Administration USD Million (2016-2021)
  • Table 89. Argentina Injectable Drug Delivery, by Devices USD Million (2016-2021)
  • Table 90. Argentina Injectable Drug Delivery, by End User USD Million (2016-2021)
  • Table 91. Rest of South America Injectable Drug Delivery, by Type USD Million (2016-2021)
  • Table 92. Rest of South America Injectable Drug Delivery, by Application USD Million (2016-2021)
  • Table 93. Rest of South America Injectable Drug Delivery, by Formulations USD Million (2016-2021)
  • Table 94. Rest of South America Injectable Drug Delivery, by Formulation Packaging USD Million (2016-2021)
  • Table 95. Rest of South America Injectable Drug Delivery, by Facility of Use USD Million (2016-2021)
  • Table 96. Rest of South America Injectable Drug Delivery, by Distribution Channel USD Million (2016-2021)
  • Table 97. Rest of South America Injectable Drug Delivery, by Usage Pattern USD Million (2016-2021)
  • Table 98. Rest of South America Injectable Drug Delivery, by Therapeutic Application USD Million (2016-2021)
  • Table 99. Rest of South America Injectable Drug Delivery, by Site of Administration USD Million (2016-2021)
  • Table 100. Rest of South America Injectable Drug Delivery, by Devices USD Million (2016-2021)
  • Table 101. Rest of South America Injectable Drug Delivery, by End User USD Million (2016-2021)
  • Table 102. Asia Pacific Injectable Drug Delivery, by Country USD Million (2016-2021)
  • Table 103. Asia Pacific Injectable Drug Delivery, by Type USD Million (2016-2021)
  • Table 104. Asia Pacific Injectable Drug Delivery, by Application USD Million (2016-2021)
  • Table 105. Asia Pacific Injectable Drug Delivery, by Formulations USD Million (2016-2021)
  • Table 106. Asia Pacific Injectable Drug Delivery, by Formulation Packaging USD Million (2016-2021)
  • Table 107. Asia Pacific Injectable Drug Delivery, by Facility of Use USD Million (2016-2021)
  • Table 108. Asia Pacific Injectable Drug Delivery, by Distribution Channel USD Million (2016-2021)
  • Table 109. Asia Pacific Injectable Drug Delivery, by Usage Pattern USD Million (2016-2021)
  • Table 110. Asia Pacific Injectable Drug Delivery, by Therapeutic Application USD Million (2016-2021)
  • Table 111. Asia Pacific Injectable Drug Delivery, by Site of Administration USD Million (2016-2021)
  • Table 112. Asia Pacific Injectable Drug Delivery, by Devices USD Million (2016-2021)
  • Table 113. Asia Pacific Injectable Drug Delivery, by End User USD Million (2016-2021)
  • Table 114. China Injectable Drug Delivery, by Type USD Million (2016-2021)
  • Table 115. China Injectable Drug Delivery, by Application USD Million (2016-2021)
  • Table 116. China Injectable Drug Delivery, by Formulations USD Million (2016-2021)
  • Table 117. China Injectable Drug Delivery, by Formulation Packaging USD Million (2016-2021)
  • Table 118. China Injectable Drug Delivery, by Facility of Use USD Million (2016-2021)
  • Table 119. China Injectable Drug Delivery, by Distribution Channel USD Million (2016-2021)
  • Table 120. China Injectable Drug Delivery, by Usage Pattern USD Million (2016-2021)
  • Table 121. China Injectable Drug Delivery, by Therapeutic Application USD Million (2016-2021)
  • Table 122. China Injectable Drug Delivery, by Site of Administration USD Million (2016-2021)
  • Table 123. China Injectable Drug Delivery, by Devices USD Million (2016-2021)
  • Table 124. China Injectable Drug Delivery, by End User USD Million (2016-2021)
  • Table 125. Japan Injectable Drug Delivery, by Type USD Million (2016-2021)
  • Table 126. Japan Injectable Drug Delivery, by Application USD Million (2016-2021)
  • Table 127. Japan Injectable Drug Delivery, by Formulations USD Million (2016-2021)
  • Table 128. Japan Injectable Drug Delivery, by Formulation Packaging USD Million (2016-2021)
  • Table 129. Japan Injectable Drug Delivery, by Facility of Use USD Million (2016-2021)
  • Table 130. Japan Injectable Drug Delivery, by Distribution Channel USD Million (2016-2021)
  • Table 131. Japan Injectable Drug Delivery, by Usage Pattern USD Million (2016-2021)
  • Table 132. Japan Injectable Drug Delivery, by Therapeutic Application USD Million (2016-2021)
  • Table 133. Japan Injectable Drug Delivery, by Site of Administration USD Million (2016-2021)
  • Table 134. Japan Injectable Drug Delivery, by Devices USD Million (2016-2021)
  • Table 135. Japan Injectable Drug Delivery, by End User USD Million (2016-2021)
  • Table 136. India Injectable Drug Delivery, by Type USD Million (2016-2021)
  • Table 137. India Injectable Drug Delivery, by Application USD Million (2016-2021)
  • Table 138. India Injectable Drug Delivery, by Formulations USD Million (2016-2021)
  • Table 139. India Injectable Drug Delivery, by Formulation Packaging USD Million (2016-2021)
  • Table 140. India Injectable Drug Delivery, by Facility of Use USD Million (2016-2021)
  • Table 141. India Injectable Drug Delivery, by Distribution Channel USD Million (2016-2021)
  • Table 142. India Injectable Drug Delivery, by Usage Pattern USD Million (2016-2021)
  • Table 143. India Injectable Drug Delivery, by Therapeutic Application USD Million (2016-2021)
  • Table 144. India Injectable Drug Delivery, by Site of Administration USD Million (2016-2021)
  • Table 145. India Injectable Drug Delivery, by Devices USD Million (2016-2021)
  • Table 146. India Injectable Drug Delivery, by End User USD Million (2016-2021)
  • Table 147. South Korea Injectable Drug Delivery, by Type USD Million (2016-2021)
  • Table 148. South Korea Injectable Drug Delivery, by Application USD Million (2016-2021)
  • Table 149. South Korea Injectable Drug Delivery, by Formulations USD Million (2016-2021)
  • Table 150. South Korea Injectable Drug Delivery, by Formulation Packaging USD Million (2016-2021)
  • Table 151. South Korea Injectable Drug Delivery, by Facility of Use USD Million (2016-2021)
  • Table 152. South Korea Injectable Drug Delivery, by Distribution Channel USD Million (2016-2021)
  • Table 153. South Korea Injectable Drug Delivery, by Usage Pattern USD Million (2016-2021)
  • Table 154. South Korea Injectable Drug Delivery, by Therapeutic Application USD Million (2016-2021)
  • Table 155. South Korea Injectable Drug Delivery, by Site of Administration USD Million (2016-2021)
  • Table 156. South Korea Injectable Drug Delivery, by Devices USD Million (2016-2021)
  • Table 157. South Korea Injectable Drug Delivery, by End User USD Million (2016-2021)
  • Table 158. Taiwan Injectable Drug Delivery, by Type USD Million (2016-2021)
  • Table 159. Taiwan Injectable Drug Delivery, by Application USD Million (2016-2021)
  • Table 160. Taiwan Injectable Drug Delivery, by Formulations USD Million (2016-2021)
  • Table 161. Taiwan Injectable Drug Delivery, by Formulation Packaging USD Million (2016-2021)
  • Table 162. Taiwan Injectable Drug Delivery, by Facility of Use USD Million (2016-2021)
  • Table 163. Taiwan Injectable Drug Delivery, by Distribution Channel USD Million (2016-2021)
  • Table 164. Taiwan Injectable Drug Delivery, by Usage Pattern USD Million (2016-2021)
  • Table 165. Taiwan Injectable Drug Delivery, by Therapeutic Application USD Million (2016-2021)
  • Table 166. Taiwan Injectable Drug Delivery, by Site of Administration USD Million (2016-2021)
  • Table 167. Taiwan Injectable Drug Delivery, by Devices USD Million (2016-2021)
  • Table 168. Taiwan Injectable Drug Delivery, by End User USD Million (2016-2021)
  • Table 169. Australia Injectable Drug Delivery, by Type USD Million (2016-2021)
  • Table 170. Australia Injectable Drug Delivery, by Application USD Million (2016-2021)
  • Table 171. Australia Injectable Drug Delivery, by Formulations USD Million (2016-2021)
  • Table 172. Australia Injectable Drug Delivery, by Formulation Packaging USD Million (2016-2021)
  • Table 173. Australia Injectable Drug Delivery, by Facility of Use USD Million (2016-2021)
  • Table 174. Australia Injectable Drug Delivery, by Distribution Channel USD Million (2016-2021)
  • Table 175. Australia Injectable Drug Delivery, by Usage Pattern USD Million (2016-2021)
  • Table 176. Australia Injectable Drug Delivery, by Therapeutic Application USD Million (2016-2021)
  • Table 177. Australia Injectable Drug Delivery, by Site of Administration USD Million (2016-2021)
  • Table 178. Australia Injectable Drug Delivery, by Devices USD Million (2016-2021)
  • Table 179. Australia Injectable Drug Delivery, by End User USD Million (2016-2021)
  • Table 180. Rest of Asia-Pacific Injectable Drug Delivery, by Type USD Million (2016-2021)
  • Table 181. Rest of Asia-Pacific Injectable Drug Delivery, by Application USD Million (2016-2021)
  • Table 182. Rest of Asia-Pacific Injectable Drug Delivery, by Formulations USD Million (2016-2021)
  • Table 183. Rest of Asia-Pacific Injectable Drug Delivery, by Formulation Packaging USD Million (2016-2021)
  • Table 184. Rest of Asia-Pacific Injectable Drug Delivery, by Facility of Use USD Million (2016-2021)
  • Table 185. Rest of Asia-Pacific Injectable Drug Delivery, by Distribution Channel USD Million (2016-2021)
  • Table 186. Rest of Asia-Pacific Injectable Drug Delivery, by Usage Pattern USD Million (2016-2021)
  • Table 187. Rest of Asia-Pacific Injectable Drug Delivery, by Therapeutic Application USD Million (2016-2021)
  • Table 188. Rest of Asia-Pacific Injectable Drug Delivery, by Site of Administration USD Million (2016-2021)
  • Table 189. Rest of Asia-Pacific Injectable Drug Delivery, by Devices USD Million (2016-2021)
  • Table 190. Rest of Asia-Pacific Injectable Drug Delivery, by End User USD Million (2016-2021)
  • Table 191. Europe Injectable Drug Delivery, by Country USD Million (2016-2021)
  • Table 192. Europe Injectable Drug Delivery, by Type USD Million (2016-2021)
  • Table 193. Europe Injectable Drug Delivery, by Application USD Million (2016-2021)
  • Table 194. Europe Injectable Drug Delivery, by Formulations USD Million (2016-2021)
  • Table 195. Europe Injectable Drug Delivery, by Formulation Packaging USD Million (2016-2021)
  • Table 196. Europe Injectable Drug Delivery, by Facility of Use USD Million (2016-2021)
  • Table 197. Europe Injectable Drug Delivery, by Distribution Channel USD Million (2016-2021)
  • Table 198. Europe Injectable Drug Delivery, by Usage Pattern USD Million (2016-2021)
  • Table 199. Europe Injectable Drug Delivery, by Therapeutic Application USD Million (2016-2021)
  • Table 200. Europe Injectable Drug Delivery, by Site of Administration USD Million (2016-2021)
  • Table 201. Europe Injectable Drug Delivery, by Devices USD Million (2016-2021)
  • Table 202. Europe Injectable Drug Delivery, by End User USD Million (2016-2021)
  • Table 203. Germany Injectable Drug Delivery, by Type USD Million (2016-2021)
  • Table 204. Germany Injectable Drug Delivery, by Application USD Million (2016-2021)
  • Table 205. Germany Injectable Drug Delivery, by Formulations USD Million (2016-2021)
  • Table 206. Germany Injectable Drug Delivery, by Formulation Packaging USD Million (2016-2021)
  • Table 207. Germany Injectable Drug Delivery, by Facility of Use USD Million (2016-2021)
  • Table 208. Germany Injectable Drug Delivery, by Distribution Channel USD Million (2016-2021)
  • Table 209. Germany Injectable Drug Delivery, by Usage Pattern USD Million (2016-2021)
  • Table 210. Germany Injectable Drug Delivery, by Therapeutic Application USD Million (2016-2021)
  • Table 211. Germany Injectable Drug Delivery, by Site of Administration USD Million (2016-2021)
  • Table 212. Germany Injectable Drug Delivery, by Devices USD Million (2016-2021)
  • Table 213. Germany Injectable Drug Delivery, by End User USD Million (2016-2021)
  • Table 214. France Injectable Drug Delivery, by Type USD Million (2016-2021)
  • Table 215. France Injectable Drug Delivery, by Application USD Million (2016-2021)
  • Table 216. France Injectable Drug Delivery, by Formulations USD Million (2016-2021)
  • Table 217. France Injectable Drug Delivery, by Formulation Packaging USD Million (2016-2021)
  • Table 218. France Injectable Drug Delivery, by Facility of Use USD Million (2016-2021)
  • Table 219. France Injectable Drug Delivery, by Distribution Channel USD Million (2016-2021)
  • Table 220. France Injectable Drug Delivery, by Usage Pattern USD Million (2016-2021)
  • Table 221. France Injectable Drug Delivery, by Therapeutic Application USD Million (2016-2021)
  • Table 222. France Injectable Drug Delivery, by Site of Administration USD Million (2016-2021)
  • Table 223. France Injectable Drug Delivery, by Devices USD Million (2016-2021)
  • Table 224. France Injectable Drug Delivery, by End User USD Million (2016-2021)
  • Table 225. Italy Injectable Drug Delivery, by Type USD Million (2016-2021)
  • Table 226. Italy Injectable Drug Delivery, by Application USD Million (2016-2021)
  • Table 227. Italy Injectable Drug Delivery, by Formulations USD Million (2016-2021)
  • Table 228. Italy Injectable Drug Delivery, by Formulation Packaging USD Million (2016-2021)
  • Table 229. Italy Injectable Drug Delivery, by Facility of Use USD Million (2016-2021)
  • Table 230. Italy Injectable Drug Delivery, by Distribution Channel USD Million (2016-2021)
  • Table 231. Italy Injectable Drug Delivery, by Usage Pattern USD Million (2016-2021)
  • Table 232. Italy Injectable Drug Delivery, by Therapeutic Application USD Million (2016-2021)
  • Table 233. Italy Injectable Drug Delivery, by Site of Administration USD Million (2016-2021)
  • Table 234. Italy Injectable Drug Delivery, by Devices USD Million (2016-2021)
  • Table 235. Italy Injectable Drug Delivery, by End User USD Million (2016-2021)
  • Table 236. United Kingdom Injectable Drug Delivery, by Type USD Million (2016-2021)
  • Table 237. United Kingdom Injectable Drug Delivery, by Application USD Million (2016-2021)
  • Table 238. United Kingdom Injectable Drug Delivery, by Formulations USD Million (2016-2021)
  • Table 239. United Kingdom Injectable Drug Delivery, by Formulation Packaging USD Million (2016-2021)
  • Table 240. United Kingdom Injectable Drug Delivery, by Facility of Use USD Million (2016-2021)
  • Table 241. United Kingdom Injectable Drug Delivery, by Distribution Channel USD Million (2016-2021)
  • Table 242. United Kingdom Injectable Drug Delivery, by Usage Pattern USD Million (2016-2021)
  • Table 243. United Kingdom Injectable Drug Delivery, by Therapeutic Application USD Million (2016-2021)
  • Table 244. United Kingdom Injectable Drug Delivery, by Site of Administration USD Million (2016-2021)
  • Table 245. United Kingdom Injectable Drug Delivery, by Devices USD Million (2016-2021)
  • Table 246. United Kingdom Injectable Drug Delivery, by End User USD Million (2016-2021)
  • Table 247. Netherlands Injectable Drug Delivery, by Type USD Million (2016-2021)
  • Table 248. Netherlands Injectable Drug Delivery, by Application USD Million (2016-2021)
  • Table 249. Netherlands Injectable Drug Delivery, by Formulations USD Million (2016-2021)
  • Table 250. Netherlands Injectable Drug Delivery, by Formulation Packaging USD Million (2016-2021)
  • Table 251. Netherlands Injectable Drug Delivery, by Facility of Use USD Million (2016-2021)
  • Table 252. Netherlands Injectable Drug Delivery, by Distribution Channel USD Million (2016-2021)
  • Table 253. Netherlands Injectable Drug Delivery, by Usage Pattern USD Million (2016-2021)
  • Table 254. Netherlands Injectable Drug Delivery, by Therapeutic Application USD Million (2016-2021)
  • Table 255. Netherlands Injectable Drug Delivery, by Site of Administration USD Million (2016-2021)
  • Table 256. Netherlands Injectable Drug Delivery, by Devices USD Million (2016-2021)
  • Table 257. Netherlands Injectable Drug Delivery, by End User USD Million (2016-2021)
  • Table 258. Rest of Europe Injectable Drug Delivery, by Type USD Million (2016-2021)
  • Table 259. Rest of Europe Injectable Drug Delivery, by Application USD Million (2016-2021)
  • Table 260. Rest of Europe Injectable Drug Delivery, by Formulations USD Million (2016-2021)
  • Table 261. Rest of Europe Injectable Drug Delivery, by Formulation Packaging USD Million (2016-2021)
  • Table 262. Rest of Europe Injectable Drug Delivery, by Facility of Use USD Million (2016-2021)
  • Table 263. Rest of Europe Injectable Drug Delivery, by Distribution Channel USD Million (2016-2021)
  • Table 264. Rest of Europe Injectable Drug Delivery, by Usage Pattern USD Million (2016-2021)
  • Table 265. Rest of Europe Injectable Drug Delivery, by Therapeutic Application USD Million (2016-2021)
  • Table 266. Rest of Europe Injectable Drug Delivery, by Site of Administration USD Million (2016-2021)
  • Table 267. Rest of Europe Injectable Drug Delivery, by Devices USD Million (2016-2021)
  • Table 268. Rest of Europe Injectable Drug Delivery, by End User USD Million (2016-2021)
  • Table 269. MEA Injectable Drug Delivery, by Country USD Million (2016-2021)
  • Table 270. MEA Injectable Drug Delivery, by Type USD Million (2016-2021)
  • Table 271. MEA Injectable Drug Delivery, by Application USD Million (2016-2021)
  • Table 272. MEA Injectable Drug Delivery, by Formulations USD Million (2016-2021)
  • Table 273. MEA Injectable Drug Delivery, by Formulation Packaging USD Million (2016-2021)
  • Table 274. MEA Injectable Drug Delivery, by Facility of Use USD Million (2016-2021)
  • Table 275. MEA Injectable Drug Delivery, by Distribution Channel USD Million (2016-2021)
  • Table 276. MEA Injectable Drug Delivery, by Usage Pattern USD Million (2016-2021)
  • Table 277. MEA Injectable Drug Delivery, by Therapeutic Application USD Million (2016-2021)
  • Table 278. MEA Injectable Drug Delivery, by Site of Administration USD Million (2016-2021)
  • Table 279. MEA Injectable Drug Delivery, by Devices USD Million (2016-2021)
  • Table 280. MEA Injectable Drug Delivery, by End User USD Million (2016-2021)
  • Table 281. Middle East Injectable Drug Delivery, by Type USD Million (2016-2021)
  • Table 282. Middle East Injectable Drug Delivery, by Application USD Million (2016-2021)
  • Table 283. Middle East Injectable Drug Delivery, by Formulations USD Million (2016-2021)
  • Table 284. Middle East Injectable Drug Delivery, by Formulation Packaging USD Million (2016-2021)
  • Table 285. Middle East Injectable Drug Delivery, by Facility of Use USD Million (2016-2021)
  • Table 286. Middle East Injectable Drug Delivery, by Distribution Channel USD Million (2016-2021)
  • Table 287. Middle East Injectable Drug Delivery, by Usage Pattern USD Million (2016-2021)
  • Table 288. Middle East Injectable Drug Delivery, by Therapeutic Application USD Million (2016-2021)
  • Table 289. Middle East Injectable Drug Delivery, by Site of Administration USD Million (2016-2021)
  • Table 290. Middle East Injectable Drug Delivery, by Devices USD Million (2016-2021)
  • Table 291. Middle East Injectable Drug Delivery, by End User USD Million (2016-2021)
  • Table 292. Africa Injectable Drug Delivery, by Type USD Million (2016-2021)
  • Table 293. Africa Injectable Drug Delivery, by Application USD Million (2016-2021)
  • Table 294. Africa Injectable Drug Delivery, by Formulations USD Million (2016-2021)
  • Table 295. Africa Injectable Drug Delivery, by Formulation Packaging USD Million (2016-2021)
  • Table 296. Africa Injectable Drug Delivery, by Facility of Use USD Million (2016-2021)
  • Table 297. Africa Injectable Drug Delivery, by Distribution Channel USD Million (2016-2021)
  • Table 298. Africa Injectable Drug Delivery, by Usage Pattern USD Million (2016-2021)
  • Table 299. Africa Injectable Drug Delivery, by Therapeutic Application USD Million (2016-2021)
  • Table 300. Africa Injectable Drug Delivery, by Site of Administration USD Million (2016-2021)
  • Table 301. Africa Injectable Drug Delivery, by Devices USD Million (2016-2021)
  • Table 302. Africa Injectable Drug Delivery, by End User USD Million (2016-2021)
  • Table 303. North America Injectable Drug Delivery, by Country USD Million (2016-2021)
  • Table 304. North America Injectable Drug Delivery, by Type USD Million (2016-2021)
  • Table 305. North America Injectable Drug Delivery, by Application USD Million (2016-2021)
  • Table 306. North America Injectable Drug Delivery, by Formulations USD Million (2016-2021)
  • Table 307. North America Injectable Drug Delivery, by Formulation Packaging USD Million (2016-2021)
  • Table 308. North America Injectable Drug Delivery, by Facility of Use USD Million (2016-2021)
  • Table 309. North America Injectable Drug Delivery, by Distribution Channel USD Million (2016-2021)
  • Table 310. North America Injectable Drug Delivery, by Usage Pattern USD Million (2016-2021)
  • Table 311. North America Injectable Drug Delivery, by Therapeutic Application USD Million (2016-2021)
  • Table 312. North America Injectable Drug Delivery, by Site of Administration USD Million (2016-2021)
  • Table 313. North America Injectable Drug Delivery, by Devices USD Million (2016-2021)
  • Table 314. North America Injectable Drug Delivery, by End User USD Million (2016-2021)
  • Table 315. United States Injectable Drug Delivery, by Type USD Million (2016-2021)
  • Table 316. United States Injectable Drug Delivery, by Application USD Million (2016-2021)
  • Table 317. United States Injectable Drug Delivery, by Formulations USD Million (2016-2021)
  • Table 318. United States Injectable Drug Delivery, by Formulation Packaging USD Million (2016-2021)
  • Table 319. United States Injectable Drug Delivery, by Facility of Use USD Million (2016-2021)
  • Table 320. United States Injectable Drug Delivery, by Distribution Channel USD Million (2016-2021)
  • Table 321. United States Injectable Drug Delivery, by Usage Pattern USD Million (2016-2021)
  • Table 322. United States Injectable Drug Delivery, by Therapeutic Application USD Million (2016-2021)
  • Table 323. United States Injectable Drug Delivery, by Site of Administration USD Million (2016-2021)
  • Table 324. United States Injectable Drug Delivery, by Devices USD Million (2016-2021)
  • Table 325. United States Injectable Drug Delivery, by End User USD Million (2016-2021)
  • Table 326. Canada Injectable Drug Delivery, by Type USD Million (2016-2021)
  • Table 327. Canada Injectable Drug Delivery, by Application USD Million (2016-2021)
  • Table 328. Canada Injectable Drug Delivery, by Formulations USD Million (2016-2021)
  • Table 329. Canada Injectable Drug Delivery, by Formulation Packaging USD Million (2016-2021)
  • Table 330. Canada Injectable Drug Delivery, by Facility of Use USD Million (2016-2021)
  • Table 331. Canada Injectable Drug Delivery, by Distribution Channel USD Million (2016-2021)
  • Table 332. Canada Injectable Drug Delivery, by Usage Pattern USD Million (2016-2021)
  • Table 333. Canada Injectable Drug Delivery, by Therapeutic Application USD Million (2016-2021)
  • Table 334. Canada Injectable Drug Delivery, by Site of Administration USD Million (2016-2021)
  • Table 335. Canada Injectable Drug Delivery, by Devices USD Million (2016-2021)
  • Table 336. Canada Injectable Drug Delivery, by End User USD Million (2016-2021)
  • Table 337. Mexico Injectable Drug Delivery, by Type USD Million (2016-2021)
  • Table 338. Mexico Injectable Drug Delivery, by Application USD Million (2016-2021)
  • Table 339. Mexico Injectable Drug Delivery, by Formulations USD Million (2016-2021)
  • Table 340. Mexico Injectable Drug Delivery, by Formulation Packaging USD Million (2016-2021)
  • Table 341. Mexico Injectable Drug Delivery, by Facility of Use USD Million (2016-2021)
  • Table 342. Mexico Injectable Drug Delivery, by Distribution Channel USD Million (2016-2021)
  • Table 343. Mexico Injectable Drug Delivery, by Usage Pattern USD Million (2016-2021)
  • Table 344. Mexico Injectable Drug Delivery, by Therapeutic Application USD Million (2016-2021)
  • Table 345. Mexico Injectable Drug Delivery, by Site of Administration USD Million (2016-2021)
  • Table 346. Mexico Injectable Drug Delivery, by Devices USD Million (2016-2021)
  • Table 347. Mexico Injectable Drug Delivery, by End User USD Million (2016-2021)
  • Table 348. Injectable Drug Delivery Sales: by Type(K Units)
  • Table 349. Injectable Drug Delivery Sales Devices , by Region K Units (2016-2021)
  • Table 350. Injectable Drug Delivery Sales Conventional Injection Device {Prefilled Syringes and Fillable Syringes} , by Region K Units (2016-2021)
  • Table 351. Injectable Drug Delivery Sales Self-injection Devices {Needle-Free Injectors (NFI), Wearable Injectors, Pen Injectors and Auto-Injectors} , by Region K Units (2016-2021)
  • Table 352. Injectable Drug Delivery Sales Auto Injectors , by Region K Units (2016-2021)
  • Table 353. Injectable Drug Delivery Sales Pen Injectors , by Region K Units (2016-2021)
  • Table 354. Injectable Drug Delivery Sales Wearable Injectors , by Region K Units (2016-2021)
  • Table 355. Injectable Drug Delivery Sales Other Devices , by Region K Units (2016-2021)
  • Table 356. Injectable Drug Delivery Sales: by Application(K Units)
  • Table 357. Injectable Drug Delivery Sales Aesthetics , by Region K Units (2016-2021)
  • Table 358. Injectable Drug Delivery Sales Autoimmune Diseases , by Region K Units (2016-2021)
  • Table 359. Injectable Drug Delivery Sales Hormonal Disorders , by Region K Units (2016-2021)
  • Table 360. Injectable Drug Delivery Sales Infectious Diseases , by Region K Units (2016-2021)
  • Table 361. Injectable Drug Delivery Sales Oncology , by Region K Units (2016-2021)
  • Table 362. Injectable Drug Delivery Sales Pain Management , by Region K Units (2016-2021)
  • Table 363. Injectable Drug Delivery Sales: by Formulation Packaging(K Units)
  • Table 364. Injectable Drug Delivery Sales Ampules , by Region K Units (2016-2021)
  • Table 365. Injectable Drug Delivery Sales Vials , by Region K Units (2016-2021)
  • Table 366. Injectable Drug Delivery Sales Cartridges , by Region K Units (2016-2021)
  • Table 367. Injectable Drug Delivery Sales Bottles , by Region K Units (2016-2021)
  • Table 368. Injectable Drug Delivery Sales: by Facility of Use(K Units)
  • Table 369. Injectable Drug Delivery Sales Hospitals and Clinics , by Region K Units (2016-2021)
  • Table 370. Injectable Drug Delivery Sales Home Care Settings , by Region K Units (2016-2021)
  • Table 371. Injectable Drug Delivery Sales Other Facilities of Use , by Region K Units (2016-2021)
  • Table 372. Injectable Drug Delivery Sales: by Distribution Channel(K Units)
  • Table 373. Injectable Drug Delivery Sales Hospitals , by Region K Units (2016-2021)
  • Table 374. Injectable Drug Delivery Sales Retail Pharmacy Stores , by Region K Units (2016-2021)
  • Table 375. Injectable Drug Delivery Sales: by Usage Pattern(K Units)
  • Table 376. Injectable Drug Delivery Sales Curative Care , by Region K Units (2016-2021)
  • Table 377. Injectable Drug Delivery Sales Immunization , by Region K Units (2016-2021)
  • Table 378. Injectable Drug Delivery Sales Other Usage , by Region K Units (2016-2021)
  • Table 379. Injectable Drug Delivery Sales: by Therapeutic Application(K Units)
  • Table 380. Injectable Drug Delivery Sales Auto-immune diseases , by Region K Units (2016-2021)
  • Table 381. Injectable Drug Delivery Sales Hormonal Disorders , by Region K Units (2016-2021)
  • Table 382. Injectable Drug Delivery Sales Orphan Diseases , by Region K Units (2016-2021)
  • Table 383. Injectable Drug Delivery Sales Oncology , by Region K Units (2016-2021)
  • Table 384. Injectable Drug Delivery Sales Other Therapeutic Applications , by Region K Units (2016-2021)
  • Table 385. Injectable Drug Delivery Sales: by Site of Administration(K Units)
  • Table 386. Injectable Drug Delivery Sales Skin {Intradermal and Subcutaneous} , by Region K Units (2016-2021)
  • Table 387. Injectable Drug Delivery Sales Circulatory/Musculoskeletal{ Intravenous, Intracardiac, Intramuscular, and Intraperitoneal} , by Region K Units (2016-2021)
  • Table 388. Injectable Drug Delivery Sales Organs {Intravitreal and Intra-Articular} , by Region K Units (2016-2021)
  • Table 389. Injectable Drug Delivery Sales Central Nervous System {Intracerebral and Intrathecal} , by Region K Units (2016-2021)
  • Table 390. Injectable Drug Delivery Sales: by Devices(K Units)
  • Table 391. Injectable Drug Delivery Sales Conventional Injection Device {Prefilled Syringes and Fillable Syringes} , by Region K Units (2016-2021)
  • Table 392. Injectable Drug Delivery Sales Self-injection Devices {Needle-Free Injectors (NFI), Wearable Injectors , by Region K Units (2016-2021)
  • Table 393. Injectable Drug Delivery Sales Pen Injectors and Auto-Injectors} , by Region K Units (2016-2021)
  • Table 394. Injectable Drug Delivery Sales Auto Injectors , by Region K Units (2016-2021)
  • Table 395. Injectable Drug Delivery Sales Pen Injectors , by Region K Units (2016-2021)
  • Table 396. Injectable Drug Delivery Sales Wearable Injectors , by Region K Units (2016-2021)
  • Table 397. Injectable Drug Delivery Sales Other Devices , by Region K Units (2016-2021)
  • Table 398. Injectable Drug Delivery Sales: by End User(K Units)
  • Table 399. Injectable Drug Delivery Sales Hospitals/Clinics , by Region K Units (2016-2021)
  • Table 400. Injectable Drug Delivery Sales Home Care Settings , by Region K Units (2016-2021)
  • Table 401. Injectable Drug Delivery Sales Research Laboratories , by Region K Units (2016-2021)
  • Table 402. Injectable Drug Delivery Sales Pharmaceutical and Biotechnology Companies , by Region K Units (2016-2021)
  • Table 403. Injectable Drug Delivery Sales Other End Users , by Region K Units (2016-2021)
  • Table 404. South America Injectable Drug Delivery Sales, by Country K Units (2016-2021)
  • Table 405. South America Injectable Drug Delivery Sales, by Type K Units (2016-2021)
  • Table 406. South America Injectable Drug Delivery Sales, by Application K Units (2016-2021)
  • Table 407. South America Injectable Drug Delivery Sales, by Formulations K Units (2016-2021)
  • Table 408. South America Injectable Drug Delivery Sales, by Formulation Packaging K Units (2016-2021)
  • Table 409. South America Injectable Drug Delivery Sales, by Facility of Use K Units (2016-2021)
  • Table 410. South America Injectable Drug Delivery Sales, by Distribution Channel K Units (2016-2021)
  • Table 411. South America Injectable Drug Delivery Sales, by Usage Pattern K Units (2016-2021)
  • Table 412. South America Injectable Drug Delivery Sales, by Therapeutic Application K Units (2016-2021)
  • Table 413. South America Injectable Drug Delivery Sales, by Site of Administration K Units (2016-2021)
  • Table 414. South America Injectable Drug Delivery Sales, by Devices K Units (2016-2021)
  • Table 415. South America Injectable Drug Delivery Sales, by End User K Units (2016-2021)
  • Table 416. Brazil Injectable Drug Delivery Sales, by Type K Units (2016-2021)
  • Table 417. Brazil Injectable Drug Delivery Sales, by Application K Units (2016-2021)
  • Table 418. Brazil Injectable Drug Delivery Sales, by Formulations K Units (2016-2021)
  • Table 419. Brazil Injectable Drug Delivery Sales, by Formulation Packaging K Units (2016-2021)
  • Table 420. Brazil Injectable Drug Delivery Sales, by Facility of Use K Units (2016-2021)
  • Table 421. Brazil Injectable Drug Delivery Sales, by Distribution Channel K Units (2016-2021)
  • Table 422. Brazil Injectable Drug Delivery Sales, by Usage Pattern K Units (2016-2021)
  • Table 423. Brazil Injectable Drug Delivery Sales, by Therapeutic Application K Units (2016-2021)
  • Table 424. Brazil Injectable Drug Delivery Sales, by Site of Administration K Units (2016-2021)
  • Table 425. Brazil Injectable Drug Delivery Sales, by Devices K Units (2016-2021)
  • Table 426. Brazil Injectable Drug Delivery Sales, by End User K Units (2016-2021)
  • Table 427. Argentina Injectable Drug Delivery Sales, by Type K Units (2016-2021)
  • Table 428. Argentina Injectable Drug Delivery Sales, by Application K Units (2016-2021)
  • Table 429. Argentina Injectable Drug Delivery Sales, by Formulations K Units (2016-2021)
  • Table 430. Argentina Injectable Drug Delivery Sales, by Formulation Packaging K Units (2016-2021)
  • Table 431. Argentina Injectable Drug Delivery Sales, by Facility of Use K Units (2016-2021)
  • Table 432. Argentina Injectable Drug Delivery Sales, by Distribution Channel K Units (2016-2021)
  • Table 433. Argentina Injectable Drug Delivery Sales, by Usage Pattern K Units (2016-2021)
  • Table 434. Argentina Injectable Drug Delivery Sales, by Therapeutic Application K Units (2016-2021)
  • Table 435. Argentina Injectable Drug Delivery Sales, by Site of Administration K Units (2016-2021)
  • Table 436. Argentina Injectable Drug Delivery Sales, by Devices K Units (2016-2021)
  • Table 437. Argentina Injectable Drug Delivery Sales, by End User K Units (2016-2021)
  • Table 438. Rest of South America Injectable Drug Delivery Sales, by Type K Units (2016-2021)
  • Table 439. Rest of South America Injectable Drug Delivery Sales, by Application K Units (2016-2021)
  • Table 440. Rest of South America Injectable Drug Delivery Sales, by Formulations K Units (2016-2021)
  • Table 441. Rest of South America Injectable Drug Delivery Sales, by Formulation Packaging K Units (2016-2021)
  • Table 442. Rest of South America Injectable Drug Delivery Sales, by Facility of Use K Units (2016-2021)
  • Table 443. Rest of South America Injectable Drug Delivery Sales, by Distribution Channel K Units (2016-2021)
  • Table 444. Rest of South America Injectable Drug Delivery Sales, by Usage Pattern K Units (2016-2021)
  • Table 445. Rest of South America Injectable Drug Delivery Sales, by Therapeutic Application K Units (2016-2021)
  • Table 446. Rest of South America Injectable Drug Delivery Sales, by Site of Administration K Units (2016-2021)
  • Table 447. Rest of South America Injectable Drug Delivery Sales, by Devices K Units (2016-2021)
  • Table 448. Rest of South America Injectable Drug Delivery Sales, by End User K Units (2016-2021)
  • Table 449. Asia Pacific Injectable Drug Delivery Sales, by Country K Units (2016-2021)
  • Table 450. Asia Pacific Injectable Drug Delivery Sales, by Type K Units (2016-2021)
  • Table 451. Asia Pacific Injectable Drug Delivery Sales, by Application K Units (2016-2021)
  • Table 452. Asia Pacific Injectable Drug Delivery Sales, by Formulations K Units (2016-2021)
  • Table 453. Asia Pacific Injectable Drug Delivery Sales, by Formulation Packaging K Units (2016-2021)
  • Table 454. Asia Pacific Injectable Drug Delivery Sales, by Facility of Use K Units (2016-2021)
  • Table 455. Asia Pacific Injectable Drug Delivery Sales, by Distribution Channel K Units (2016-2021)
  • Table 456. Asia Pacific Injectable Drug Delivery Sales, by Usage Pattern K Units (2016-2021)
  • Table 457. Asia Pacific Injectable Drug Delivery Sales, by Therapeutic Application K Units (2016-2021)
  • Table 458. Asia Pacific Injectable Drug Delivery Sales, by Site of Administration K Units (2016-2021)
  • Table 459. Asia Pacific Injectable Drug Delivery Sales, by Devices K Units (2016-2021)
  • Table 460. Asia Pacific Injectable Drug Delivery Sales, by End User K Units (2016-2021)
  • Table 461. China Injectable Drug Delivery Sales, by Type K Units (2016-2021)
  • Table 462. China Injectable Drug Delivery Sales, by Application K Units (2016-2021)
  • Table 463. China Injectable Drug Delivery Sales, by Formulations K Units (2016-2021)
  • Table 464. China Injectable Drug Delivery Sales, by Formulation Packaging K Units (2016-2021)
  • Table 465. China Injectable Drug Delivery Sales, by Facility of Use K Units (2016-2021)
  • Table 466. China Injectable Drug Delivery Sales, by Distribution Channel K Units (2016-2021)
  • Table 467. China Injectable Drug Delivery Sales, by Usage Pattern K Units (2016-2021)
  • Table 468. China Injectable Drug Delivery Sales, by Therapeutic Application K Units (2016-2021)
  • Table 469. China Injectable Drug Delivery Sales, by Site of Administration K Units (2016-2021)
  • Table 470. China Injectable Drug Delivery Sales, by Devices K Units (2016-2021)
  • Table 471. China Injectable Drug Delivery Sales, by End User K Units (2016-2021)
  • Table 472. Japan Injectable Drug Delivery Sales, by Type K Units (2016-2021)
  • Table 473. Japan Injectable Drug Delivery Sales, by Application K Units (2016-2021)
  • Table 474. Japan Injectable Drug Delivery Sales, by Formulations K Units (2016-2021)
  • Table 475. Japan Injectable Drug Delivery Sales, by Formulation Packaging K Units (2016-2021)
  • Table 476. Japan Injectable Drug Delivery Sales, by Facility of Use K Units (2016-2021)
  • Table 477. Japan Injectable Drug Delivery Sales, by Distribution Channel K Units (2016-2021)
  • Table 478. Japan Injectable Drug Delivery Sales, by Usage Pattern K Units (2016-2021)
  • Table 479. Japan Injectable Drug Delivery Sales, by Therapeutic Application K Units (2016-2021)
  • Table 480. Japan Injectable Drug Delivery Sales, by Site of Administration K Units (2016-2021)
  • Table 481. Japan Injectable Drug Delivery Sales, by Devices K Units (2016-2021)
  • Table 482. Japan Injectable Drug Delivery Sales, by End User K Units (2016-2021)
  • Table 483. India Injectable Drug Delivery Sales, by Type K Units (2016-2021)
  • Table 484. India Injectable Drug Delivery Sales, by Application K Units (2016-2021)
  • Table 485. India Injectable Drug Delivery Sales, by Formulations K Units (2016-2021)
  • Table 486. India Injectable Drug Delivery Sales, by Formulation Packaging K Units (2016-2021)
  • Table 487. India Injectable Drug Delivery Sales, by Facility of Use K Units (2016-2021)
  • Table 488. India Injectable Drug Delivery Sales, by Distribution Channel K Units (2016-2021)
  • Table 489. India Injectable Drug Delivery Sales, by Usage Pattern K Units (2016-2021)
  • Table 490. India Injectable Drug Delivery Sales, by Therapeutic Application K Units (2016-2021)
  • Table 491. India Injectable Drug Delivery Sales, by Site of Administration K Units (2016-2021)
  • Table 492. India Injectable Drug Delivery Sales, by Devices K Units (2016-2021)
  • Table 493. India Injectable Drug Delivery Sales, by End User K Units (2016-2021)
  • Table 494. South Korea Injectable Drug Delivery Sales, by Type K Units (2016-2021)
  • Table 495. South Korea Injectable Drug Delivery Sales, by Application K Units (2016-2021)
  • Table 496. South Korea Injectable Drug Delivery Sales, by Formulations K Units (2016-2021)
  • Table 497. South Korea Injectable Drug Delivery Sales, by Formulation Packaging K Units (2016-2021)
  • Table 498. South Korea Injectable Drug Delivery Sales, by Facility of Use K Units (2016-2021)
  • Table 499. South Korea Injectable Drug Delivery Sales, by Distribution Channel K Units (2016-2021)
  • Table 500. South Korea Injectable Drug Delivery Sales, by Usage Pattern K Units (2016-2021)
  • Table 501. South Korea Injectable Drug Delivery Sales, by Therapeutic Application K Units (2016-2021)
  • Table 502. South Korea Injectable Drug Delivery Sales, by Site of Administration K Units (2016-2021)
  • Table 503. South Korea Injectable Drug Delivery Sales, by Devices K Units (2016-2021)
  • Table 504. South Korea Injectable Drug Delivery Sales, by End User K Units (2016-2021)
  • Table 505. Taiwan Injectable Drug Delivery Sales, by Type K Units (2016-2021)
  • Table 506. Taiwan Injectable Drug Delivery Sales, by Application K Units (2016-2021)
  • Table 507. Taiwan Injectable Drug Delivery Sales, by Formulations K Units (2016-2021)
  • Table 508. Taiwan Injectable Drug Delivery Sales, by Formulation Packaging K Units (2016-2021)
  • Table 509. Taiwan Injectable Drug Delivery Sales, by Facility of Use K Units (2016-2021)
  • Table 510. Taiwan Injectable Drug Delivery Sales, by Distribution Channel K Units (2016-2021)
  • Table 511. Taiwan Injectable Drug Delivery Sales, by Usage Pattern K Units (2016-2021)
  • Table 512. Taiwan Injectable Drug Delivery Sales, by Therapeutic Application K Units (2016-2021)
  • Table 513. Taiwan Injectable Drug Delivery Sales, by Site of Administration K Units (2016-2021)
  • Table 514. Taiwan Injectable Drug Delivery Sales, by Devices K Units (2016-2021)
  • Table 515. Taiwan Injectable Drug Delivery Sales, by End User K Units (2016-2021)
  • Table 516. Australia Injectable Drug Delivery Sales, by Type K Units (2016-2021)
  • Table 517. Australia Injectable Drug Delivery Sales, by Application K Units (2016-2021)
  • Table 518. Australia Injectable Drug Delivery Sales, by Formulations K Units (2016-2021)
  • Table 519. Australia Injectable Drug Delivery Sales, by Formulation Packaging K Units (2016-2021)
  • Table 520. Australia Injectable Drug Delivery Sales, by Facility of Use K Units (2016-2021)
  • Table 521. Australia Injectable Drug Delivery Sales, by Distribution Channel K Units (2016-2021)
  • Table 522. Australia Injectable Drug Delivery Sales, by Usage Pattern K Units (2016-2021)
  • Table 523. Australia Injectable Drug Delivery Sales, by Therapeutic Application K Units (2016-2021)
  • Table 524. Australia Injectable Drug Delivery Sales, by Site of Administration K Units (2016-2021)
  • Table 525. Australia Injectable Drug Delivery Sales, by Devices K Units (2016-2021)
  • Table 526. Australia Injectable Drug Delivery Sales, by End User K Units (2016-2021)
  • Table 527. Rest of Asia-Pacific Injectable Drug Delivery Sales, by Type K Units (2016-2021)
  • Table 528. Rest of Asia-Pacific Injectable Drug Delivery Sales, by Application K Units (2016-2021)
  • Table 529. Rest of Asia-Pacific Injectable Drug Delivery Sales, by Formulations K Units (2016-2021)
  • Table 530. Rest of Asia-Pacific Injectable Drug Delivery Sales, by Formulation Packaging K Units (2016-2021)
  • Table 531. Rest of Asia-Pacific Injectable Drug Delivery Sales, by Facility of Use K Units (2016-2021)
  • Table 532. Rest of Asia-Pacific Injectable Drug Delivery Sales, by Distribution Channel K Units (2016-2021)
  • Table 533. Rest of Asia-Pacific Injectable Drug Delivery Sales, by Usage Pattern K Units (2016-2021)
  • Table 534. Rest of Asia-Pacific Injectable Drug Delivery Sales, by Therapeutic Application K Units (2016-2021)
  • Table 535. Rest of Asia-Pacific Injectable Drug Delivery Sales, by Site of Administration K Units (2016-2021)
  • Table 536. Rest of Asia-Pacific Injectable Drug Delivery Sales, by Devices K Units (2016-2021)
  • Table 537. Rest of Asia-Pacific Injectable Drug Delivery Sales, by End User K Units (2016-2021)
  • Table 538. Europe Injectable Drug Delivery Sales, by Country K Units (2016-2021)
  • Table 539. Europe Injectable Drug Delivery Sales, by Type K Units (2016-2021)
  • Table 540. Europe Injectable Drug Delivery Sales, by Application K Units (2016-2021)
  • Table 541. Europe Injectable Drug Delivery Sales, by Formulations K Units (2016-2021)
  • Table 542. Europe Injectable Drug Delivery Sales, by Formulation Packaging K Units (2016-2021)
  • Table 543. Europe Injectable Drug Delivery Sales, by Facility of Use K Units (2016-2021)
  • Table 544. Europe Injectable Drug Delivery Sales, by Distribution Channel K Units (2016-2021)
  • Table 545. Europe Injectable Drug Delivery Sales, by Usage Pattern K Units (2016-2021)
  • Table 546. Europe Injectable Drug Delivery Sales, by Therapeutic Application K Units (2016-2021)
  • Table 547. Europe Injectable Drug Delivery Sales, by Site of Administration K Units (2016-2021)
  • Table 548. Europe Injectable Drug Delivery Sales, by Devices K Units (2016-2021)
  • Table 549. Europe Injectable Drug Delivery Sales, by End User K Units (2016-2021)
  • Table 550. Germany Injectable Drug Delivery Sales, by Type K Units (2016-2021)
  • Table 551. Germany Injectable Drug Delivery Sales, by Application K Units (2016-2021)
  • Table 552. Germany Injectable Drug Delivery Sales, by Formulations K Units (2016-2021)
  • Table 553. Germany Injectable Drug Delivery Sales, by Formulation Packaging K Units (2016-2021)
  • Table 554. Germany Injectable Drug Delivery Sales, by Facility of Use K Units (2016-2021)
  • Table 555. Germany Injectable Drug Delivery Sales, by Distribution Channel K Units (2016-2021)
  • Table 556. Germany Injectable Drug Delivery Sales, by Usage Pattern K Units (2016-2021)
  • Table 557. Germany Injectable Drug Delivery Sales, by Therapeutic Application K Units (2016-2021)
  • Table 558. Germany Injectable Drug Delivery Sales, by Site of Administration K Units (2016-2021)
  • Table 559. Germany Injectable Drug Delivery Sales, by Devices K Units (2016-2021)
  • Table 560. Germany Injectable Drug Delivery Sales, by End User K Units (2016-2021)
  • Table 561. France Injectable Drug Delivery Sales, by Type K Units (2016-2021)
  • Table 562. France Injectable Drug Delivery Sales, by Application K Units (2016-2021)
  • Table 563. France Injectable Drug Delivery Sales, by Formulations K Units (2016-2021)
  • Table 564. France Injectable Drug Delivery Sales, by Formulation Packaging K Units (2016-2021)
  • Table 565. France Injectable Drug Delivery Sales, by Facility of Use K Units (2016-2021)
  • Table 566. France Injectable Drug Delivery Sales, by Distribution Channel K Units (2016-2021)
  • Table 567. France Injectable Drug Delivery Sales, by Usage Pattern K Units (2016-2021)
  • Table 568. France Injectable Drug Delivery Sales, by Therapeutic Application K Units (2016-2021)
  • Table 569. France Injectable Drug Delivery Sales, by Site of Administration K Units (2016-2021)
  • Table 570. France Injectable Drug Delivery Sales, by Devices K Units (2016-2021)
  • Table 571. France Injectable Drug Delivery Sales, by End User K Units (2016-2021)
  • Table 572. Italy Injectable Drug Delivery Sales, by Type K Units (2016-2021)
  • Table 573. Italy Injectable Drug Delivery Sales, by Application K Units (2016-2021)
  • Table 574. Italy Injectable Drug Delivery Sales, by Formulations K Units (2016-2021)
  • Table 575. Italy Injectable Drug Delivery Sales, by Formulation Packaging K Units (2016-2021)
  • Table 576. Italy Injectable Drug Delivery Sales, by Facility of Use K Units (2016-2021)
  • Table 577. Italy Injectable Drug Delivery Sales, by Distribution Channel K Units (2016-2021)
  • Table 578. Italy Injectable Drug Delivery Sales, by Usage Pattern K Units (2016-2021)
  • Table 579. Italy Injectable Drug Delivery Sales, by Therapeutic Application K Units (2016-2021)
  • Table 580. Italy Injectable Drug Delivery Sales, by Site of Administration K Units (2016-2021)
  • Table 581. Italy Injectable Drug Delivery Sales, by Devices K Units (2016-2021)
  • Table 582. Italy Injectable Drug Delivery Sales, by End User K Units (2016-2021)
  • Table 583. United Kingdom Injectable Drug Delivery Sales, by Type K Units (2016-2021)
  • Table 584. United Kingdom Injectable Drug Delivery Sales, by Application K Units (2016-2021)
  • Table 585. United Kingdom Injectable Drug Delivery Sales, by Formulations K Units (2016-2021)
  • Table 586. United Kingdom Injectable Drug Delivery Sales, by Formulation Packaging K Units (2016-2021)
  • Table 587. United Kingdom Injectable Drug Delivery Sales, by Facility of Use K Units (2016-2021)
  • Table 588. United Kingdom Injectable Drug Delivery Sales, by Distribution Channel K Units (2016-2021)
  • Table 589. United Kingdom Injectable Drug Delivery Sales, by Usage Pattern K Units (2016-2021)
  • Table 590. United Kingdom Injectable Drug Delivery Sales, by Therapeutic Application K Units (2016-2021)
  • Table 591. United Kingdom Injectable Drug Delivery Sales, by Site of Administration K Units (2016-2021)
  • Table 592. United Kingdom Injectable Drug Delivery Sales, by Devices K Units (2016-2021)
  • Table 593. United Kingdom Injectable Drug Delivery Sales, by End User K Units (2016-2021)
  • Table 594. Netherlands Injectable Drug Delivery Sales, by Type K Units (2016-2021)
  • Table 595. Netherlands Injectable Drug Delivery Sales, by Application K Units (2016-2021)
  • Table 596. Netherlands Injectable Drug Delivery Sales, by Formulations K Units (2016-2021)
  • Table 597. Netherlands Injectable Drug Delivery Sales, by Formulation Packaging K Units (2016-2021)
  • Table 598. Netherlands Injectable Drug Delivery Sales, by Facility of Use K Units (2016-2021)
  • Table 599. Netherlands Injectable Drug Delivery Sales, by Distribution Channel K Units (2016-2021)
  • Table 600. Netherlands Injectable Drug Delivery Sales, by Usage Pattern K Units (2016-2021)
  • Table 601. Netherlands Injectable Drug Delivery Sales, by Therapeutic Application K Units (2016-2021)
  • Table 602. Netherlands Injectable Drug Delivery Sales, by Site of Administration K Units (2016-2021)
  • Table 603. Netherlands Injectable Drug Delivery Sales, by Devices K Units (2016-2021)
  • Table 604. Netherlands Injectable Drug Delivery Sales, by End User K Units (2016-2021)
  • Table 605. Rest of Europe Injectable Drug Delivery Sales, by Type K Units (2016-2021)
  • Table 606. Rest of Europe Injectable Drug Delivery Sales, by Application K Units (2016-2021)
  • Table 607. Rest of Europe Injectable Drug Delivery Sales, by Formulations K Units (2016-2021)
  • Table 608. Rest of Europe Injectable Drug Delivery Sales, by Formulation Packaging K Units (2016-2021)
  • Table 609. Rest of Europe Injectable Drug Delivery Sales, by Facility of Use K Units (2016-2021)
  • Table 610. Rest of Europe Injectable Drug Delivery Sales, by Distribution Channel K Units (2016-2021)
  • Table 611. Rest of Europe Injectable Drug Delivery Sales, by Usage Pattern K Units (2016-2021)
  • Table 612. Rest of Europe Injectable Drug Delivery Sales, by Therapeutic Application K Units (2016-2021)
  • Table 613. Rest of Europe Injectable Drug Delivery Sales, by Site of Administration K Units (2016-2021)
  • Table 614. Rest of Europe Injectable Drug Delivery Sales, by Devices K Units (2016-2021)
  • Table 615. Rest of Europe Injectable Drug Delivery Sales, by End User K Units (2016-2021)
  • Table 616. MEA Injectable Drug Delivery Sales, by Country K Units (2016-2021)
  • Table 617. MEA Injectable Drug Delivery Sales, by Type K Units (2016-2021)
  • Table 618. MEA Injectable Drug Delivery Sales, by Application K Units (2016-2021)
  • Table 619. MEA Injectable Drug Delivery Sales, by Formulations K Units (2016-2021)
  • Table 620. MEA Injectable Drug Delivery Sales, by Formulation Packaging K Units (2016-2021)
  • Table 621. MEA Injectable Drug Delivery Sales, by Facility of Use K Units (2016-2021)
  • Table 622. MEA Injectable Drug Delivery Sales, by Distribution Channel K Units (2016-2021)
  • Table 623. MEA Injectable Drug Delivery Sales, by Usage Pattern K Units (2016-2021)
  • Table 624. MEA Injectable Drug Delivery Sales, by Therapeutic Application K Units (2016-2021)
  • Table 625. MEA Injectable Drug Delivery Sales, by Site of Administration K Units (2016-2021)
  • Table 626. MEA Injectable Drug Delivery Sales, by Devices K Units (2016-2021)
  • Table 627. MEA Injectable Drug Delivery Sales, by End User K Units (2016-2021)
  • Table 628. Middle East Injectable Drug Delivery Sales, by Type K Units (2016-2021)
  • Table 629. Middle East Injectable Drug Delivery Sales, by Application K Units (2016-2021)
  • Table 630. Middle East Injectable Drug Delivery Sales, by Formulations K Units (2016-2021)
  • Table 631. Middle East Injectable Drug Delivery Sales, by Formulation Packaging K Units (2016-2021)
  • Table 632. Middle East Injectable Drug Delivery Sales, by Facility of Use K Units (2016-2021)
  • Table 633. Middle East Injectable Drug Delivery Sales, by Distribution Channel K Units (2016-2021)
  • Table 634. Middle East Injectable Drug Delivery Sales, by Usage Pattern K Units (2016-2021)
  • Table 635. Middle East Injectable Drug Delivery Sales, by Therapeutic Application K Units (2016-2021)
  • Table 636. Middle East Injectable Drug Delivery Sales, by Site of Administration K Units (2016-2021)
  • Table 637. Middle East Injectable Drug Delivery Sales, by Devices K Units (2016-2021)
  • Table 638. Middle East Injectable Drug Delivery Sales, by End User K Units (2016-2021)
  • Table 639. Africa Injectable Drug Delivery Sales, by Type K Units (2016-2021)
  • Table 640. Africa Injectable Drug Delivery Sales, by Application K Units (2016-2021)
  • Table 641. Africa Injectable Drug Delivery Sales, by Formulations K Units (2016-2021)
  • Table 642. Africa Injectable Drug Delivery Sales, by Formulation Packaging K Units (2016-2021)
  • Table 643. Africa Injectable Drug Delivery Sales, by Facility of Use K Units (2016-2021)
  • Table 644. Africa Injectable Drug Delivery Sales, by Distribution Channel K Units (2016-2021)
  • Table 645. Africa Injectable Drug Delivery Sales, by Usage Pattern K Units (2016-2021)
  • Table 646. Africa Injectable Drug Delivery Sales, by Therapeutic Application K Units (2016-2021)
  • Table 647. Africa Injectable Drug Delivery Sales, by Site of Administration K Units (2016-2021)
  • Table 648. Africa Injectable Drug Delivery Sales, by Devices K Units (2016-2021)
  • Table 649. Africa Injectable Drug Delivery Sales, by End User K Units (2016-2021)
  • Table 650. North America Injectable Drug Delivery Sales, by Country K Units (2016-2021)
  • Table 651. North America Injectable Drug Delivery Sales, by Type K Units (2016-2021)
  • Table 652. North America Injectable Drug Delivery Sales, by Application K Units (2016-2021)
  • Table 653. North America Injectable Drug Delivery Sales, by Formulations K Units (2016-2021)
  • Table 654. North America Injectable Drug Delivery Sales, by Formulation Packaging K Units (2016-2021)
  • Table 655. North America Injectable Drug Delivery Sales, by Facility of Use K Units (2016-2021)
  • Table 656. North America Injectable Drug Delivery Sales, by Distribution Channel K Units (2016-2021)
  • Table 657. North America Injectable Drug Delivery Sales, by Usage Pattern K Units (2016-2021)
  • Table 658. North America Injectable Drug Delivery Sales, by Therapeutic Application K Units (2016-2021)
  • Table 659. North America Injectable Drug Delivery Sales, by Site of Administration K Units (2016-2021)
  • Table 660. North America Injectable Drug Delivery Sales, by Devices K Units (2016-2021)
  • Table 661. North America Injectable Drug Delivery Sales, by End User K Units (2016-2021)
  • Table 662. United States Injectable Drug Delivery Sales, by Type K Units (2016-2021)
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Injectable Drug Delivery: by Type USD Million (2016-2021)
  • Figure 5. Global Injectable Drug Delivery: by Application USD Million (2016-2021)
  • Figure 6. Global Injectable Drug Delivery: by Formulation Packaging USD Million (2016-2021)
  • Figure 7. Global Injectable Drug Delivery: by Facility of Use USD Million (2016-2021)
  • Figure 8. Global Injectable Drug Delivery: by Distribution Channel USD Million (2016-2021)
  • Figure 9. Global Injectable Drug Delivery: by Usage Pattern USD Million (2016-2021)
  • Figure 10. Global Injectable Drug Delivery: by Therapeutic Application USD Million (2016-2021)
  • Figure 11. Global Injectable Drug Delivery: by Site of Administration USD Million (2016-2021)
  • Figure 12. Global Injectable Drug Delivery: by Devices USD Million (2016-2021)
  • Figure 13. Global Injectable Drug Delivery: by End User USD Million (2016-2021)
  • Figure 14. South America Injectable Drug Delivery Share (%), by Country
  • Figure 15. Asia Pacific Injectable Drug Delivery Share (%), by Country
  • Figure 16. Europe Injectable Drug Delivery Share (%), by Country
  • Figure 17. MEA Injectable Drug Delivery Share (%), by Country
  • Figure 18. North America Injectable Drug Delivery Share (%), by Country
  • Figure 19. Global Injectable Drug Delivery: by Type K Units (2016-2021)
  • Figure 20. Global Injectable Drug Delivery: by Application K Units (2016-2021)
  • Figure 21. Global Injectable Drug Delivery: by Formulation Packaging K Units (2016-2021)
  • Figure 22. Global Injectable Drug Delivery: by Facility of Use K Units (2016-2021)
  • Figure 23. Global Injectable Drug Delivery: by Distribution Channel K Units (2016-2021)
  • Figure 24. Global Injectable Drug Delivery: by Usage Pattern K Units (2016-2021)
  • Figure 25. Global Injectable Drug Delivery: by Therapeutic Application K Units (2016-2021)
  • Figure 26. Global Injectable Drug Delivery: by Site of Administration K Units (2016-2021)
  • Figure 27. Global Injectable Drug Delivery: by Devices K Units (2016-2021)
  • Figure 28. Global Injectable Drug Delivery: by End User K Units (2016-2021)
  • Figure 29. South America Injectable Drug Delivery Share (%), by Country
  • Figure 30. Asia Pacific Injectable Drug Delivery Share (%), by Country
  • Figure 31. Europe Injectable Drug Delivery Share (%), by Country
  • Figure 32. MEA Injectable Drug Delivery Share (%), by Country
  • Figure 33. North America Injectable Drug Delivery Share (%), by Country
  • Figure 34. Global Injectable Drug Delivery: by Type USD/Units (2016-2021)
  • Figure 35. Global Injectable Drug Delivery share by Players 2021 (%)
  • Figure 36. Global Injectable Drug Delivery share by Players (Top 3) 2021(%)
  • Figure 37. Global Injectable Drug Delivery share by Players (Top 5) 2021(%)
  • Figure 38. BCG Matrix for key Companies
  • Figure 39. Dickinson and Company (United States) Revenue, Net Income and Gross profit
  • Figure 40. Dickinson and Company (United States) Revenue: by Geography 2021
  • Figure 41. Baxter International (United States) Revenue, Net Income and Gross profit
  • Figure 42. Baxter International (United States) Revenue: by Geography 2021
  • Figure 43. Pfizer (United States) Revenue, Net Income and Gross profit
  • Figure 44. Pfizer (United States) Revenue: by Geography 2021
  • Figure 45. Gerresheimer AG (Germany) Revenue, Net Income and Gross profit
  • Figure 46. Gerresheimer AG (Germany) Revenue: by Geography 2021
  • Figure 47. Schott AG (Germany) Revenue, Net Income and Gross profit
  • Figure 48. Schott AG (Germany) Revenue: by Geography 2021
  • Figure 49. Eli Lilly and Company (United States) Revenue, Net Income and Gross profit
  • Figure 50. Eli Lilly and Company (United States) Revenue: by Geography 2021
  • Figure 51. Terumo Corporation (Japan) Revenue, Net Income and Gross profit
  • Figure 52. Terumo Corporation (Japan) Revenue: by Geography 2021
  • Figure 53. Sandoz (Germany) Revenue, Net Income and Gross profit
  • Figure 54. Sandoz (Germany) Revenue: by Geography 2021
  • Figure 55. Teva Pharmaceutical Industries Ltd. (Israel) Revenue, Net Income and Gross profit
  • Figure 56. Teva Pharmaceutical Industries Ltd. (Israel) Revenue: by Geography 2021
  • Figure 57. Nova Nordisk A/S (Denmark) Revenue, Net Income and Gross profit
  • Figure 58. Nova Nordisk A/S (Denmark) Revenue: by Geography 2021
  • Figure 59. Sanofi (France) Revenue, Net Income and Gross profit
  • Figure 60. Sanofi (France) Revenue: by Geography 2021
  • Figure 61. Global Injectable Drug Delivery: by Type USD Million (2022-2027)
  • Figure 62. Global Injectable Drug Delivery: by Application USD Million (2022-2027)
  • Figure 63. Global Injectable Drug Delivery: by Formulation Packaging USD Million (2022-2027)
  • Figure 64. Global Injectable Drug Delivery: by Facility of Use USD Million (2022-2027)
  • Figure 65. Global Injectable Drug Delivery: by Distribution Channel USD Million (2022-2027)
  • Figure 66. Global Injectable Drug Delivery: by Usage Pattern USD Million (2022-2027)
  • Figure 67. Global Injectable Drug Delivery: by Therapeutic Application USD Million (2022-2027)
  • Figure 68. Global Injectable Drug Delivery: by Site of Administration USD Million (2022-2027)
  • Figure 69. Global Injectable Drug Delivery: by Devices USD Million (2022-2027)
  • Figure 70. Global Injectable Drug Delivery: by End User USD Million (2022-2027)
  • Figure 71. South America Injectable Drug Delivery Share (%), by Country
  • Figure 72. Asia Pacific Injectable Drug Delivery Share (%), by Country
  • Figure 73. Europe Injectable Drug Delivery Share (%), by Country
  • Figure 74. MEA Injectable Drug Delivery Share (%), by Country
  • Figure 75. North America Injectable Drug Delivery Share (%), by Country
  • Figure 76. Global Injectable Drug Delivery: by Type K Units (2022-2027)
  • Figure 77. Global Injectable Drug Delivery: by Application K Units (2022-2027)
  • Figure 78. Global Injectable Drug Delivery: by Formulation Packaging K Units (2022-2027)
  • Figure 79. Global Injectable Drug Delivery: by Facility of Use K Units (2022-2027)
  • Figure 80. Global Injectable Drug Delivery: by Distribution Channel K Units (2022-2027)
  • Figure 81. Global Injectable Drug Delivery: by Usage Pattern K Units (2022-2027)
  • Figure 82. Global Injectable Drug Delivery: by Therapeutic Application K Units (2022-2027)
  • Figure 83. Global Injectable Drug Delivery: by Site of Administration K Units (2022-2027)
  • Figure 84. Global Injectable Drug Delivery: by Devices K Units (2022-2027)
  • Figure 85. Global Injectable Drug Delivery: by End User K Units (2022-2027)
  • Figure 86. South America Injectable Drug Delivery Share (%), by Country
  • Figure 87. Asia Pacific Injectable Drug Delivery Share (%), by Country
  • Figure 88. Europe Injectable Drug Delivery Share (%), by Country
  • Figure 89. MEA Injectable Drug Delivery Share (%), by Country
  • Figure 90. North America Injectable Drug Delivery Share (%), by Country
  • Figure 91. Global Injectable Drug Delivery: by Type USD/Units (2022-2027)
List of companies from research coverage that are profiled in the study
  • Dickinson and Company (United States)
  • Baxter International (United States)
  • Pfizer (United States)
  • Gerresheimer AG (Germany)
  • Schott AG (Germany)
  • Eli Lilly and Company (United States)
  • Terumo Corporation (Japan)
  • Sandoz (Germany)
  • Teva Pharmaceutical Industries Ltd. (Israel)
  • Nova Nordisk A/S (Denmark)
  • Sanofi (France)
Additional players considered in the study are as follows:
Crossject (France) , Injex Pharma AG (Germany) , Unilife Corporation (United States) , West Pharmaceutical Services, Inc. (United States) , Vetter Pharma-Fertigung gmbh & Co. KG (Germany)
Select User Access Type

Key Highlights of Report


Apr 2024 214 Pages 80 Tables Base Year: 2023 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now
Global Injectable Drug Delivery research Quantitative research analysis
Global Injectable Drug Delivery research Qualitative Industry Analysis
DOWNLOAD SAMPLE PDF

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Frequently Asked Questions (FAQ):

Top performing companies in the Global Injectable Drug Delivery market are Dickinson and Company (United States), Baxter International (United States), Pfizer (United States), Gerresheimer AG (Germany), Schott AG (Germany), Eli Lilly and Company (United States), Terumo Corporation (Japan), Sandoz (Germany), Teva Pharmaceutical Industries Ltd. (Israel), Nova Nordisk A/S (Denmark) and Sanofi (France), to name a few.
North America is dominating the Injectable Drug Delivery Market.
"Preference for Other Modes of Drug Delivery" is seen as one of the major challenges by many Industry Players of Injectable Drug Delivery Market
The Injectable Drug Delivery market study includes a random mix of players, including both market leaders and some top growing emerging players. Connect with our sales executive to get complete companies available in our research coverage.
The Injectable Drug Delivery market is expected to see a steady growth rate during projected year 2021 to 2027.

Know More About Global Injectable Drug Delivery research Report?

Have a Query? Click Here

Other Related Reports

Anthrax Vaccines Comprehensive Study by Type (Live Vaccines, Cell free PA Vaccines), Application (Human Use, Animal Use), Disease Type (Cutaneous Anthrax, Gastrointestinal Anthrax, Inhalation Anthrax...
$ 3450
Fibrin Glue Comprehensive Study by Type (Hemostat, Adhesive, Sealant), Application (Hemostasis, Sealing, Tissue Gluing, Support for Wound Healing, Arein cardiac surgery, Burn to bleed, Pulmonary su...
$ 3450
Lignocaine Comprehensive Study by Application (Local Anesthesia, Dentistry, Cardiac Arrhythmia, Epilepsy, Cosmetics, Anti-Arrhythmic, Others), Formulations (Injections, Creams, Ointments, Gels, Aeros...
$ 3450
Pediatric Medicines Comprehensive Study by Application (Hospital, Clinic), Forms (Capsule, Liquid, Ointment, Powder), Diseases (Anemia, Chickenpox, Fever, Asthma, Others), Distribution Channel (Onli...
$ 3800
Anesthesia Masks Comprehensive Study by Type (Oral {Reusable Anesthesia Face Mask and Disposable Anesthesia Face Mask}, Nasopharyngeal {Reusable Anesthesia Face Mask and Disposable Anesthesia Face Ma...
$ 3650
Skin Care Peels Comprehensive Study by Type (TCA Peels, Lactic Peels, Beta Peels, Glycolic Chemical Peels, Vitalize Peels, Pigment Balancing Peels, Bio Revitalization Peel, Other), Treatment (Acne Tr...
$ 3800